Abstract: Nonviral gene transfer is markedly enhanced by the application of in vivo electroporation (also denoted electrogene transfer or electrokinetic enhancement). This approach is safe and can be used to deliver nucleic acid fragments, oligonucleotides, siRNA, and plasmids to a wide variety of tissues, such as skeletal muscle, skin and liver. In this review, we address the principles of electroporation and demonstrate its effectiveness in disease models. Electroporation has been shown to be equally applicable to small and large animals (rodents, dogs, pigs, other farm animals and primates), and this addresses one of the major problems in gene therapy, that of scalability to humans. Gene transfer can be optimized and tissue injury minimized by the selection of appropriate electrical parameters. We and others have applied this approach in preclinical autoimmune and/or inflammatory diseases to deliver either cytokines, anti-inflammatory agents or immunoregulatory molecules. Electroporation is also effective for the intratumoral delivery of therapeutic vectors. It strongly boost DNA vaccination against infectious agents (e.g., hepatitis B virus, human immunodeficiency virus-1) or tumor antigens (e.g., HER-2/neu, carcinoembryonic antigen). In addition, we found that electroporation-enhanced DNA vaccination against islet-cell antigens ameliorated autoimmune diabetes. One of the most likely future applications, however, may be in intramuscular gene transfer for systemic delivery of either endocrine hormones (e.g., growth hormone releasing hormone and leptin), hematopoietic factors (e.g., erythropoietin, GM-CSF), antibodies, enzymes, or numerous other protein drugs. In vivo electroporation has been performed in humans, and it seems likely it could be applied clinically for nonviral gene therapy.
INTRODUCTION
The success of gene therapy depends on the efficient insertion of genes into appropriate target cells, without causing cell injury, oncogenic mutation or inflammation. It should also be possible to re-administer the vector several times, especially in the treatment of chronic diseases. Few vector technologies meet all these requirements. Although the majority of gene therapy studies have been performed with viral vectors, they have serious limitations in terms of immunogenicity and pathogenicity. Nonviral (primarily plasmidbased) gene therapy raises fewer safety concerns, and is not hampered by vector immunogenicity if properly designed (by systematic removal of CpG islands and residual bacterial sequences), permitting re-administration of the vector. Historically, the simple injection of naked plasmid DNA into muscle has been sufficient to produce therapeutic levels of cytokines, anti-inflammatory agents, and other mediators [Piccirillo, C.A. et al., 2003; Prud'homme, G.J. et al., 2001a; Prud'homme, G.J. et al., 2001b] , although levels of gene expression are generally much lower than with viral vectors. Indeed, a major limitation of nonviral gene therapy has been low transfection efficiency, but this can be ameliorated sufficiently to rival viral vectors in many applications. In various tissues, transfection has been enhanced or accomplished by: 1) "gene gun" delivery (usually DNA-coated gold particles propelled into cells); 2) jet injection of DNA (e.g., Biojector); 3) hydrodynamic (intravascular) methods; and 4) by cationic agents such as linear or branched polymers (e.g., polyethylenimines [PEIs] ) or cationic liposomes [Akhtar, S., 2005; El-Aneed, A., 2004; Patil, S.D. et al., 2005; Wells, D.J., 2004; Wolff and Budker, 2005] . These methods have their own drawbacks. Gene gun delivery is limited to exposed tissues, intravascular methods often require injection of large volumes of fluid that are not applicable to humans, while complexes of DNA and cationic lipids or polymers can be unstable, inflammatory and even toxic.
One of the most versatile and efficient methods of enhancing gene transfer involves the application of electric field pulses after the injection of nucleic acids (DNA, RNA and/or oligonucleotides) into tissues. While the exact mechanism for increased uptake of nucleic acids is under debate, it is clear that the electric pulses transiently increase membrane permeability, allowing direct entry of macromolecules, and thus avoiding the cellular degradation pathway [Liu, F. et al., 2006] . The method is safe provided appropriate electrical parameters are chosen. The transfection efficiency of electroporation (EP) is many times greater than that of naked DNA injection, with markedly reduced interanimal variability [Andre, F. et al., 2004] . EP-enhanced nonviral gene transfer is also referred to as in vivo EP and electrogene transfer, and is the focus of this review.
As an approach to protein drug delivery, plasmid-based electrogene transfer has been proven safe and effective in preclinical models of immunological, endocrine, neoplastic and other diseases. Recent studies have shown that EP powerfully boosts DNA vaccines; these results generated a greater clinical interest in this form of immunization. In addition, EP-enhanced in vivo administration of nucleic acid segments such as oligodeoxynucleotides (ODNs) or short inhibitory RNA (siRNA) is highly promising in the therapy of a wide variety of diseases.
IN VIVO ELECTROPORATION -PRINCIPLES AND PLASMIDS

Principles
Traditionally, plasmid-based technology has been limited in scope because expression levels following naked DNA transfer have been low, only a fraction of viral-mediated gene transfer. Numerous investigators have outlined the safety and toxicological concerns of injecting viruses for delivery of transgenes to animals and humans [Pilaro, A.M. et al., 1999] . A more efficient level of plasmid DNA transfer and transgene expression can be accomplished by utilizing a series of square-wave electric pulses to drive naked DNA into a stable, non-dividing population of cells. Efficient procedures for EP in vivo have been used for a few years [Aihara, H. et al., 1998 ]. However, the exact mechanism of EP is still much unknown. The cell membrane, normally not permeable to large molecules, including DNA, is thought to be equivalent to an electrical capacitor . The physical process of EP exposes the target tissue to brief electric field pulses that induces temporary and reversible breakdown of the cell membrane and the formation of pores [Mir, L.M. et al., 1999] . The lipidic membrane of the cell can be considered as a dielectric element placed between the extracellular environment and the cytoplasm. When cells are exposed to an electric field, structural defects in the membrane or opening and enlarging pores will be induced. During the period of membrane destabilization, a variety of charged macromolecules, including drugs, and nucleic acids such as plasmids, may gain intracellular access. The general mechanism of electrogene transfer clearly begins with a temporary increase in membrane permeability resulting from the electric pulses, followed by the diffusion of molecules through the membrane. The question is how DNA diffuses across the permeabilized membrane, through a passive mechanism or through the effects of electrophoretic force. It is also generally accepted that electric pulses could induce electrophoresis, which may be critical for in vivo gene transfer [Bureau, M.F. et al., 2000; Satkauskas, S. et al., 2005; Satkauskas, S. et al., 2002] . Nevertheless, this last hypothesis has been recently challenged [Liu, F. et al., 2006] and a passive mechanism involving simple diffusion of DNA through the membranes was proposed. While the actual mechanism remains controversial, numerous studies have focused on the rather practical aspects of EP: optimum conditions of nucleic acid delivery, which result in long-term high transgene expression levels, without pain or tissue damage.
Plasmid Constructs for Nonviral Gene Therapy
Plasmid Backbone (to be or not to be useful: CpG in DNA Vaccination Versus Gene Therapy)
A plasmid-based mammalian expression system is composed of a plasmid backbone and an expression cassette. The plasmid backbone typically contains a bacterial ori and a selection gene that are necessary for the specific growth of only the bacteria that are transformed with the proper plasmid. However, the nucleotide sequence of bacterial genes can adversely affect the expression level for therapeutic transgenes when a mammalian host receives the plasmid DNA, to possible gene silencing [Shi, H. et al., 2002; Shiraishi, M. et al., 2002] . Conversely, DNA vaccines, in general, have been found to be poorly immunogenic in nonhuman primates and humans as compared with mice. As the immunogenicity of DNA plasmids relies, to a large extent, on the presence of CpG motifs as built in adjuvants, plasmids or oligonucleotides used for vaccination purposes may be enriched in immunostimulatory sequences, such as CpG islands [Coban, C. et al., 2005; Kennedy, N.J. et al., 2005; Payette, P.J. et al., 2006] . Thus, although useful for DNA vaccination, CpG motifs can have negative effects on other gene transfer applications. First, CpG-mediated nonspecific inflammatory effects might directly injure tissues, and/or confuse the interpretation of immunological studies. Second, the cytomegalovirus immediate early enhancer promoter (CMV IE-EP), and other viral promoters, are turned off by inflammatory cytokines [particularly interferon-γ (IFNγ) and tumor necrosis factor α (TNFα)] [Bromberg, J.S. et al., 1998; Chen, D. et al., 2003; Qin, L. et al., 1997] . Because most plasmids carry large numbers of CpG motifs, it is not easy to eliminate them completely. Nevertheless, some recently available commercial plasmid vectors are devoid of CpG elements, even in sequences coding for reporter genes (e.g., InvivoGen, San Diego, CA). This is possible because of the eight codons that contain CG, all can be substituted by at least two other codons that code for the same amino acid. Also, in our laboratory we designed new plasmid backbones (pAV0201 series) and synthetically produce them. Using optimized backbone plasmids, we obtained long-term transgene expression at physiologic levels in various mammals, including cows and dogs [Khan, A.S. et al., 2005a; Tone, C.M. et al., 2004] .
An alternative approach involves deletion of most vector elements, to produce minicircles containing only, or primarily, the expression cassette [Chen, Z.Y. et al., 2003; Darquet, A.M. et al., 1999] . These small vectors transfect cells more efficiently, presumably because of their small size. Furthermore, they lack all the CpG sequences of the vector backbone, and retain only those that might be present in essential transcriptional elements (these can also often be replaced). Minicircle DNA vectors are remarkable for the level and persistence of transgene expression. Indeed, minicircular DNAs lacking bacterial sequences expressed 45-and 560-fold more serum human factor IX and alpha1-antitrypsin, respectively, compared to standard plasmid DNAs transfected into mouse liver [Chen, Z.Y. et al., 2003] .
Undoubtedly, vectors that have been modified for a reduction in CpG motifs will have significant advantages for many forms of gene therapy, where the activation of innate immunity is not desirable. On the other hand, CpG motifs are beneficial in the treatment of allergic diseases and in cancer gene therapy [Klinman, D.M., 2004] . Thus, when developing tools for certain applications, one should consider synthetically produced plasmids, with small codon-optimized backbones, including only sequences of choice and logically correlated with their application. Furthermore, projecting the therapeutic approaches to a clinical success implies reasonable cost-of-goods -many of the newest sequences have an optimized ori, resulting in high production yields and thus being economically advantageous.
Expression Cassette
Tissue-Specific and Ubiquitous Promoters
While most studies using electroporation of different tissues were conducted using plasmids with expression cassettes driven by ubiquitous promoters, especially the CMV promoter, numerous strategies have been employed to create or integrate tissue-specific promoters and use them for therapeutic purposes [Keogh, M.C. et al., 1999; Roell, W. et al., 2002; Rothermel, B.A. et al., 2001] . These promoters are designed to combine the long-lasting properties of tissuespecific promoters with the strength of ubiquitous sequences. Electroporation was thus employed in a two-fold approach: 1) to test the tissue-specific promoters, especially for potency and length of expression, 2) to drive the expression of transgenes to the target tissue or organ, and assay therapeutic endpoints.
For instance, in our laboratory, we have performed an analysis of the organization of strong muscle promoters and enhancers and their interactions with myogenic regulatory factors that led us to construct synthetic muscle-specific promoters (SP), with a transcriptional potency which exceeds that of any naturally occurring promoters [Li, X. et al., 1999] . Initial studies in rodents using plasmid/EP have been used to determine the relative strength of synthetic musclespecific promoters compared to the CMV promoter (Fig. 1) , at both short-and long-term post-injection. Numerous subsequent studies using direct muscle injection followed by constant-current electroporation on large mammals, including pigs, cattle and dogs, have shown strong and long-lasting expression when constructs under the control of promoters such as synthetic promoter c5-12 (SPc5-12) were used . Experiments to determine the relative potency or promoter organization (transcription factors binding sites, position of enhancing elements, etc.) have been performed by others for muscle fast IIB fiber-specific and nervedependent aldolase A pM promoter [Bertrand, A. et al., 2003] , ocular-specific promoters, such as a vitelliform macular dystrophy 2 (VMD2) promoter [Kachi, S. et al., Fig. (1) . Representative images of gastrocnemius muscle (cross-sectional and longitudinal) expressing GFP under the control of various promoters, both ubiquitious and synthetic muscle-specific in mice are depicted. All animals recived 10 µg plasmid in a total volume of 25 µl. The muscles were collected 8 days post-treatment and analyzed for GFP expression. Expression under the control of ubiquitous promoter (CMV) yields lower expression than those using synthetic muscle-specific promoters (c2-26, c6-39, c5-12) . Control animals were sham electroporated.
2005], cystatin-related epididymal spermatogenic and gamma-glutamyl transpeptidase promoter, which are highly expressed in the initial segment of the epididymis and are regulated by luminal testicular factors [Kirby, J.L. et al., 2004] , or fatty acid binding protein promoters in the liver [Fujishiro, K. et al., 2002] .
Signal Peptides
Numerous studies that reported good but short-lived expression after transgene delivery in vivo implicated yet other factors, and suggested potential solutions. Another step in the direction of developing plasmids for realistic therapeutic and vaccination protocols that go beyond the mouse is the choice and design of transgene, its species specificity, as well as its leader and signal peptides. In many cases, the signal peptide sequence is sufficient to target the newly synthesized protein to a specific secretory pathway [Baertschi, A.J. et al., 2001; El Meskini, R. et al., 2001] . In our laboratory, we showed that the human signal peptide of growth hormone releasing hormone (GHRH) is more efficient in promoting secretion than other species-specific signal peptides, for instance cat peptide (1:2.2 intracellular peptide versus secreted peptide, P<0.04) both in vitro in muscle cells and in vivo after plasmid injection with EP. When synthetic signal peptides created by analysis of neuropeptide signal sequences were included in our constructs, we observed further increased secretion (ratio of 1:5 intracellular peptide versus secreted peptide, P<0.002) as compared to controls (natural signal peptide) .
Recently, studies in large animal species, such as nonhuman primates that received an erythropoietin encoding plasmid showed that changing the transgene leader sequence and optimizing the gene codon usage yields higher levels of circulating transgene product and a more significant biological effect than the wild-type gene . Similar results have been obtained using DNA vaccines delivered by EP. For example, most house dust mite allergic patients react to Der p 1 from Dermatophagoides pteronyssinus (a major trigger of allergy and atopic asthma worldwide), which is a cysteine protease and the catalytic effects of Der p 1 vaccination may be unpredictable. Investigators proposed an approach to reduce this risk by vaccinating with DNA encoding enzymatically inactive forms of dust mite Der p 1, without its native pre-pro sequences, which was substituted by another leader sequence. This potently induced Der p 1-specific antibodies. However, without any pre-pro sequence, the same DNA fragment was well expressed but failed to induce significant levels of anti-Der p 1 antibodies, without further boosting by protein [Wolfowicz, C.B. et al., 2003] . Thus, by altering the plasmid design and sequence, it is possible to minimize the dose necessary to attain physiological levels of the target hormone, enzyme, or peptide, and to manipulate the expression of the newly produced transgene product.
siRNA AND ITS USES IN GENE SILENCING
It is now well established that small double strand RNAs (dsRNAs), usually 19 to 28 nucleotides (nt) long, are involved in a ubiquitous post-transcriptional mechanism of gene silencing, often called RNA interference (RNAi) [Aigner, A., 2006; Dykxhoorn, D.M. et al., 2006; Kim, V.N., 2005; McCaffrey, A.P. et al., 2002; Mocellin, S. et al., 2006] . Gene silencing is mediated by double-stranded siRNAs, or the closely related micro RNAs (miRNAs) derived from endogenous hairpin precursors. siRNAs or miRNAs can bind to an RNA-induced silencing complex (RISC) and either degrade messenger RNA (mRNA), block translation, or otherwise suppress gene expression in a sequence-specific manner. In the cell, small RNAs that mediate gene silencing are produced from larger dsRNAs species (linear or hairpin) through cleavage by RNAse III enzymes. Interestingly, recent work suggests that the human RISC is a complex of Dicer, the dsRNA binding protein [transactivation response binding protein (TRBP)], and Ago2 [Gregory, R.I. et al., 2005] . Dicer has RNAse III activity and cuts dsRNA into short siRNA segments, while Ago2 actually cleaves the target mRNA. This association of components is likely very important, and it promotes greater RISC activity through interaction with precursor miRNAs (a substrate of Dicer) compared to shorter (22nt) siRNA segments. It might explain why dsRNAs that are 25 to 30nt in length, requiring Dicer processing, induce superior RNAi than shorter segments [Dykxhoorn, D.M. et al., 2006] . RNAi provides a stronger method of gene silencing than either antisense molecules or ribozymes. The small RNAs are generally short enough to avoid or minimize induction of an interferon response, and this increases their therapeutic potential. Not surprisingly, several in vivo research and therapeutic applications have been reported. However, therapy with siRNAs is complicated by the fact that these are highly charged molecules that do not easily enter cells. To address this problem, various delivery strategies have been devised. It is reasonably simple to deliver siRNAs to cells in vitro, with methods such as cationic lipids or electroporation, but delivery in vivo is more difficult. For in vivo administration, hydrodynamic delivery and electroporation have both been employed. For example, some investigators [Lewis, D.L. et al., 2002; McCaffrey, A.P. et al., 2002] silenced genes in vivo in mice by injecting siRNA in the tail vein under pressure. Liver uptake of siRNA was observed, and a sequence-specific gene silencing effect in that organ persisted for 3 or 4 days. Other studies showed that the intravenous injection of Fas-specific siRNA protected against hepatitis and hepatic necrosis induced by administration of either concanavalin A (Con A) or anti-Fas monoclonal antibodies [Song, E. et al., 2003] . Caspase 8 siRNA also protected against acute liver failure in similar models [Zender, L. et al., 2003] . Remarkably, improved survival due to caspase 8 RNA interference was observed when treatment was applied during ongoing acute liver failure. A limitation of systemic hydrodynamic delivery is that the siRNA is distributed to multiple organs and, furthermore, the large volume of fluids required (relative to body size) could not be administered to humans.
Hagstrom et al. [Hagstrom, J.E. et al., 2004] demonstrated delivery of plasmid DNA or siRNA by injection into the distal veins of limbs transiently isolated from the circulation by a tourniquet. Delivery to myocytes was facilitated by the rapid injection of sufficient volume to permit extravasation of the nucleic acid solution into muscle tissue. With this method, they reported siRNA-mediated gene silencing in rat and primate limb muscle. Kishida et al. [Kishida, T. et al., 2004] delivered siRNA duplexes corresponding to reporter genes by EP into the tibialis muscle of mice expressing these reporter genes (transgenic or vector induced). As little as 0.05µg of siRNA almost completely blocked the expression of a reporter gene from 10µg of plasmid DNA, for at least 1wk. In transgenic mice, green fluorescent protein (GFP) expression was also effectively blocked in cells receiving the complementary siRNA.
EP allows siRNA delivery to almost any tissue. As an example, Takabatake et al., [Takabatake, Y. et al., 2005] injected of synthetic siRNAs via the renal artery followed by electroporation to silence a gene in the glomerulus. siRNA targeting of enhanced green fluorescent protein (EGFP) in rats reduced endogenous (transgenic) EGFP expression, primarily in glomerular mesangial cells. Moreover, RNAi targeting against transforming growth factor β-1 (TGF-β1) depressed TGF-β1 mRNA and protein expression, and reduced matrix expansion in experimental glomerulonephritis. For cancer therapy, genes can be silenced by intratumoral injection of appropriate siRNA (or siRNA plasmid vector as described below), and local electroporation . Some disadvantages of these siRNA-based methods include the high cost of producing sufficient quantities of siRNA, transient in vivo activity and, in some cases, distribution of the siRNA to tissues outside the target area. These limitations can be circumvented by the administration of siRNA plasmid or viral (adenoviral, retroviral or lentiviral) vectors [Devroe, E. et al., 2004; Fountaine, T.M. et al., 2005; Lu, P.Y. et al., 2005; Morris, K.V. et al., 2004; Morris, K.V. et al., 2006; Sioud, M., 2005; . Viral vectors, however, are limited by the biological effects they produce, and nonviral methods are often preferable. Furthermore, nonviral methods can be adapted for both systemic and tissue-specific delivery. For example, target tissues have included tumors or limb muscle. Most of these vectors advantageously employ Polymerase III (Pol III) promoters such as U6, tRNA or H1, although Pol II constructs are feasible [Pai, S.I. et al., 2005] . Various designs are possible [Pai, S.I. et al., 2005] , e.g., vectors producing two separate complementary RNA strands or producing short hairpin RNAs (shRNAs). The shRNAs are processed in vivo by Dicer, to generate active siRNAs. The vector can also produce a modified miRNA that is also processed by Dicer. The use of plasmid or viral vectors allows the introduction of tissue-specific or drug-sensitive promoters, to either limit expression to a target tissue or limit expression to a desired period of time. The applications of siRNA technology are numerous and, in addition to therapeutic applications, it represents a powerful research tool for studying physiological and pathological gene function.
OLIGONUCLEOTIDES
Oligonucleotides have been used in a variety of circumstances in conjunction with in vivo electroporation. Fluorescein isothiocynate (FITC)-labeled oligonucleotides have been used to assess formulation effects (ionic concentration, effects of calcium, magnesium, potassium) on the electroporation efficacy in vivo [Suzuki, T. et al., 2003] . Morpholino oligonucleotides delivered by in vivo electroporation to knock-out different genes during organ differentiation has also beem proposed as a reverse genetic approach that allows researchers to quickly assess the function of genes known to be expressed, screen genes for functional relevance, and assign genes to the molecular pathways during organogenesis and regeneration [Thummel, R. et al., 2006] . DNA-cleaving deoxyribozymes (DNAzymes), a novel class of DNA oligonucleotides that can catalytically cleave target mRNAs and thereby transiently decrease gene expression in vivo have also been successfully delivered to the vasculature using EP [Nunamaker, E.A. et al. , 2003 ]. The method proved useful for the study of physiological processes in living animals. Oligonucleotides containing CpG motifs were used as adjuvant for vaccination protocols [Smooker, P.M. et al., 2004; Zhao, Y.G. et al., 2005] . On the therapeutic side, antisense oligonucleotides delivered by injection/ electroporation were used to induce exon skipping leading to generation of an in-frame dystrophin protein product in a Duchenne muscular dystrophy mouse model [Wells, K.E. et al., 2003] . Dystrophin expression was present in 20 to 30% of fibers in tibialis anterior muscle after a single injection.
METHODS, EQUIPMENT AND PARAMETERS
A series of technologies have been developed to deliver electric pulses in vivo. A summary of available devices, parameter ranges and the most recent articles describing experiments performed with the aforementioned equipment is included (Table 1).
Target Tissues
Since 1998, more than 90 transgenes have been used to achieve significant in vivo endpoints in response to the circulating levels of their respective protein products. The optimum conditions of electroporation (including for instance the choice of pulse shape, pulse amplitude and length) in a multitude of situations was summarized in Tables 1 to 7 rather than in the text, as these conditions are highly dependent on target tissue, formulation, type of application (therapeutic vs. vaccination), device and type of electrodes used, etc. The type of electrodes is also highly dependent on the target species and organ. While external (caliper, tweezers, plates, etc.) electrodes can be successfully used in rodents or for skin electroporation, internal electrodes are needed for instance for the EP of muscle and skin in larger animals. While many organs and tissues have been electroporated, most of these studies used skeletal muscle as the target organ.
Skeletal Muscle
Since the initial report by Aihara and Miyazaki [Aihara, H. et al., 1998 ], in vivo EP of the skeletal muscle for delivery of therapeutic proteins has become widely used. Although the devices, EP conditions, methods of delivery, vectors and animal models substantially differ, all studies conclude that intramuscular plasmid injection followed by EP can be successfully used to deliver therapeutic genes. Plasmid delivery in conjunction with EP allows the muscle to be used as a bioreactor for the persistent, long-term production and secretion of proteins into the blood stream. The post-mitotic nature of the muscle fibers combined with excellent vascularization, relatively easy access to numeorus groups of muscle and the potential for localized expression makes this tissue a target of choice for both basic research (study of mus-cle physiology and changes associated with specific pathological conditions) to gene therapy. Expression levels are increased by as much as 2 to 3 orders of magnitude over plasmid injection alone, to levels comparable to those of viral-mediated gene delivery, and in many cases reach physiological or therapeutically acceptable ranges.
Several studies and applications are described in detail in the following sections. A number of recent review articles address one or another aspect of these proposed therapies [Bloquel, C. et al., 2004b; McMahon, J.M. et al., 2004; Ratanamart and Shaw, 2006; Wolff, J.A. et al., 2005] . The duration of gene expression was reported to be at least 9 to 19 months after in vivo gene electrotransfer into skeletal muscle [Bettan, M. et al., 2000; Muramatsu, T. et al., 2001a; Tone, C.M. et al., 2004] . The more than 300 reported studies using direct intramuscular (i.m.) injection of plasmid followed by EP provide the evidence that adequate levels of secreted (and in some case intracellular) proteins can be achieved using plasmids in a simple, safe and efficient manner, with significant potential for gene transfer and vaccination for large animals and humans ( Table 2) . Only very recently was EP also recognized as a reliable method to enhance DNA vaccine delivery [Babiuk, L.A. et al., 2003; Scheerlinck, J.P. et al., 2004; Wu, C.J. et al., 2004] . For instance, a single injection of plasmid encoding neuraminidase from influenza virus followed by EP in mice was able to provide long-term protection from influenza . The adequate levels of protein or antigen production and maintenance of levels of expression in concordance with therapeutic or vaccination needs may now require the inclusion of regulatory sequences on the nonviral vectors [Abruzzese, R.V. et al., 2000; Draghia-Akli, R. et al., 2002b; Rizzuto, G. et al., 1999; Terada, Y. et al., 2001] .
Liver
The liver is one of the primary targets for gene therapy of numerous metabolic diseases, cancers, hepatitis and other pathologies ( Table 3) . Organ-specific targeting and expression is favored by the fact that hepatocytes have a slow turnover rate outside of disease conditions. Nevertheless, in the case of non-corrective therapies, re-administration is a prerequisite to a successful long-term therapy. Also, a gene therapy for deficiencies in intracellular enzymes or structural proteins requires functional correction at the cell level, thus targeting the largest number of cells is a major factor determining therapeutic success. While recombinant viral vectors have been widely used to introduce new genes into the liver, their usefulness may be mitigated by side effects, potential safety concerns, and the immunologic reaction to viral components, often precluding redosing [Favre, D. et al., 2001; Nathwani, A.C. et al., 2002; Reynolds, P.N. et al., 2001; Thoma, C. et al., 2000] . Plasmid delivered to hepatic vasculature [Liu, F. et al., 2001] , by hydrodynamic methods [Liu, F. et al., 1999; Zhang, G. et al., 1999] or by EP constitutes an alternative method to deliver transgenes to the liver. EP is traditionally performed in conjunction with chemotherapy for different malignancies. This treatment, electrochemotherapy, has been successful for liver malignancies in animal models [Jaroszeski, M.J. et al., 2001] . Recently, tumor reduction has been achieved by locally injecting DNA to the site of interest in the liver followed by the electric field application [Gilbert, R. et al., 2002; Harada, N. et al., 2004] . In [Glahder, J. et al., 2005; Persson, B.R. et al., 2003] ADViSYS, Inc. http://www.advisys.net EKD 0.1 to 1.5Amps / 1 to 55ms [Brown, P.A. et al., 2004; Khan, A.S. et al., 2005b] BTX (Harvard Apparatus) http://www.btxonline.com ECM 830 5 to 500V/10µs to 10s or 30 to 3000V/10 to 600µs [Dobashi, M. et al., 2005b; Liu, F. et al., 2006; Otten, G.R. et al., 2005; Rambabu, K.M. et al., 2005; Zhang, L. et al., 2003 ]3]
ECM 630 10 to 500V or 50 to 500V [Iversen, N. et al., 2005] Cyto Pulse Sciences http://www.cytopulse.com PA-4000S 5 to 1100V/1µs to 2ms [Roos, A.K. et al., 2006; Schakman, O. et al., 2005] 
Plasmid/Drug Formulation Electrodes Refs
Liver (tumor) Balb/c mice 10 pulses, 50ms, 150V/cm, 950ms between pulses saline Electrode-tungsten needles [Harada, N. et al., 2004] Liver (tumor) Sprague-Dawley rats 6 pulses, 99µs, 500 to 1500V/cm Bleomycin Six needles in circular array [Jaroszeski, M.J. et al., 2001] Liver (lobe) CD-1 mice 8 pulses, 20ms, 250V/cm, 1 to 5min after injection Normal saline Tweezertrode [Liu, F. et al., 2002] Liver (lobe) mice 6 pulses, 20ms, 200V/cm Normal saline Tweezertrode [Liu, F. et al., 2001] addition, nutritionally regulated transgene expression in vivo is attainable locally in the liver by this method [Muramatsu, T. et al., 2001b] . A method for efficient gene transfer to the liver by EP following tail vein administration of the naked DNA has been described [Liu, F. et al., 2002] . The method was recently further refined. When combining intravenous reporter gene plasmid injection with EP the expression level increased up to 200,000-fold compared to plasmid injection alone [Sakai, M. et al., 2005] . Also, the strategy of RNAibased gene silencing in combination with EP provides a possible complement to the limited therapeutic options currently available for chronic hepatitis B or C virus infection . These advances in liver gene delivery may provide powerful tools for basic research or potential clinical application studies.
Skin
DNA delivery to skin (Table 4) is emerging as a technique for DNA vaccinations and other gene transfer applications requiring local or systemic distribution of a transgene product for a shorter period of time [Zhang, L. et al., 2002] . This choice is facilitated by information which shows that EP of skin induces a mild and reversible impairment of the barrier function of the skin, a decrease in skin resistance, and a transient decrease in blood flow. Microscopic studies revealed inflammatory responses in the epidermis following EP using 10-30 millisecond pulses of voltages of 200 to 300V/cm in a rabbit model [Medi, B.M. et al., 2006] . However, these changes due to EP were reversible within a week. Neither long-term inflammation nor necroses are generally observed [Dujardin, N. et al., 2001; Dujardin, N. et al., 2002] . After direct plasmid injection into skin, transfected cells are typically restricted to the epidermis. However, in different animal species, when EP is applied after the injection, larger numbers of adipocytes and fibroblasts and numerous dendritic-like cells within the dermal and subdermal tissues, as well as lymph nodes draining electropermeabilized sites, are transfected [Drabick, J.J. et al. , 2001; Glasspool-Malone, J. et al., 2000; Watkins, C. et al., 1999] . EP has been used to enhance the transdermal delivery of methotrexate [Wong, T.W. et al., 2005] . Delivery of therapeutic plasmids into skin, for example expressing keratinocyte growth factor, has been shown to improve wound healing in a mouse model of wound-healing [Marti, G. et al., 2004] . DNA vaccines, such as plasmids expressing the hepatitis B surface antigen can be efficiently produced by skin cells and can elicit humoral and cellular responses [Medi, B.M. et al., 2005] following plasmid injection and EP. As some classic vaccines are administered to the skin, there is a logical theoretical choice of the skin as a target organ for vaccination. Nevertheless, optimized EP conditions for skin, especially in large animal models, have yet to be determined or described.
Tumors
Electrochemotherapy, or enhanced delivery of chemotherapeutic drugs, especially bleomycin, and more recently cisplatin [Rebersek, M. et al., 2004] , to accessible solid tumors has been used successfully for many years . Clinical trials using this method for the treatment of solid tumors have been and are being conducted in humans [Belehradek, M. et al., 1993; Heller, R. et al., 1996; Mir, L.M. et al., 1997; Rodriguez-Cuevas, S. et al., 2001] . Recently, investigators focused on intratumoral plasmid delivery as a means to increase long-term anti-tumor immunity [Heller, L. et al., 2000; Lucas, M.L. et al., 2001; Lucas, M.L. et al., 2002] , to inhibit angiogenesis [Cichon, T. et al., 2002; Wang, F. et al., 2002] or to reduce tumor volume [Shibata, M.A. et al., 2002] . Studies have shown that the intratumoral electrotransfer of genes is more effective than intramuscular electrotransfer of the same gene in the eradication of established tumors [such as interleukin (IL)-12], [Harada, N. et al., 2004; . These differences have been explained by the underlying immunological mechanisms, Tcell infiltration, cytotoxic T-lymphocyte (CTL) activity, direct inhibition of angiogenesis, etc. . Updated overviews of the therapeutic perspectives of anti-tumor [Zhang, L. et al., 2002] drug and DNA electrotransfer are also of significant interest [Gothelf, A. et al., 2003; Stevenson, F.K. et al., 2004] . A summary of the conditions used for these different applications is included (Table 5) .
Suicide gene therapy using HSVtk/ganciclovir technology suppressed the growth and metastasis of subcutaneously grafted mammary tumors in mice, although no complete regression was noted [Shibata, M.A. et al., 2002] . Significant inhibition of tumor growth was also obtained by intratumoral EP of TNF-related apoptosis-inducing ligand (TRAIL/Apo2 ligand), an apoptosis inducer [Yamashita, Y. et al., 2002] . In another study, electroporation-mediated intramuscular injection of an expression plasmid encoding tissue inhibitor of matrix metalloproteinase 4 (TIMP-4) resulted in sustained plasma TIMP-4 levels and significant tumor suppression [Celiker, M.Y. et al., 2001] . Some authors have also shown that intratumoral EP of an antisense of MBD2, an enzyme involved in DNA methylation, results in a serious inhibition of tumor growth in a human tumor model grafted in nude mice [Ivanov, M.A. et al., 2003] . EP of plasmids encoding cytokines into tumors has been widely used. IFN-α [Li, S. et al., 2002] , IL-12 and/or IL-18 [Kishida, T. et al., 2001; Tamura, T. et al., 2001] have been shown to reduce tumor growth and increase survival times in different tumor models.
We performed EP with endostatin (angiostatic agent) and IL-12 in a murine Lewis lung carcinoma (LLC) tumor model (subcutaneous transplantation). Fifty µg of reporter plasmid DNA were injected into LLC tumors, followed by EP using different electrical parameters. Optimal electrical pulses (300 V/cm, 20 msec) enhanced gene transfer by over 1000 fold.
We next tested the effectiveness of transferring IL-12 (p35/p40 single-chain construct) and endostatin plasmids by EP. Interestingly, injection of a mock plasmid by itself inhibited tumor growth, a result that was also reported by others [Heller, L.C. et al., 2002] . This may result from the activation of innate immunity by CpG-containing sequences of plasmid DNA [Heller, L.C. et al., 2002] . In our experiments, the endostatin gene had only a mild effect. However, in accord with other studies, intra-tumoral electrogene transfers of the IL-12 gene resulted in significant inhibition of tumor growth or in some cases, complete tumor regression (G. Prud'homme, unpublished observations).
Eye
Recently, mild electric pulse-mediated plasmid transfer (3 to 6V/mm) has been used to deliver transgenes to cornea and retina in an effort to ensure expression of a desired protein either for treatment of a local disease or in proof-ofconcept studies validating new methodology [Kachi, S. et al., 2005] . Results of these studies demonstrate that EP is an excellent method for delivering genes to multiple cell layers within the cornea with high levels of gene expression and little, if any, inflammatory response or tissue damage [BlairParks, K. et al., 2002; . Retinal cells also have been targeted. After a first demonstration showing retrograde labeling of up to 41% of the total ganglion cells in the electro-injected area , other studies with brain-derived neurotrophic factor (BDNF) gene transferred by in vivo EP showed protection of axotomized retinal ganglion cells against apoptosis ; furthermore, subretinal injection of plasmid encoding for the integrase from the bacteriophage [Shibata, M.A. et al., 2002] phiC31 was used succesfully to confer long-term gene expression in the retina by means of genomic integration [Chalberg, T.W. et al. , 2005] . A summary of the conditions used for these different applications is included (Table 6) .
Other Tissues and Organs
Smooth and Cardiac Muscle, Spleen, Joints and Testes
Smooth and Cardiac Muscle -Electroporation works well in vivo for gene delivery to smooth muscle, including vascular [Dean, D.A., 2003; Nunamaker, E.A. et al., 2003] , airway [hado-Aranda, D. et al., 2005] , bladder , and intestinal smooth muscle [Abud, H.E. et al., 2004; Ghartey-Tagoe, E.B. et al., 2005] . Due to the anatomical constrains, in most of the studies, the DNA was delivered inside the cavity or lumen before the application of the electric filed, rather than directly into the organ/tissue. Special electrodes, such as "spoon" or "balloon" electrodes have been used in these studies. Two studies have looked at the EP of cardiac muscle. An extensive review regarding the techniques, instruments and characteristics of the EP pulses for smooth and cardiac muscle has recently been published [Dean, D.A., 2003] .
Joint -In the last 3 years, a new target emerged for the use of EP -the arthritis-affected joint. EP ameliorated methotrexate therapy in the joint in a rodent model of arthritis [Tada, M. et al., 2005] . Others demonstrated the transfer of a GFP reporter plasmid in joints by EP, and this was not associated with tissue damage [Grossin, L. et al., 2003] . Potential therapeutic molecules include IL-4 and IL-1 receptor antagonist (Ra) , which have been delivered systemically but could readily be applied to the joint. Very recently investigators demonstrated that electrotransfer of siRNA complex made efficient and specific gene knockdown possible in the articular synovium. Thus, electrotransfer of siRNA was successfully applied to joints in the treatment of collageninduced arthritis (CIA) in rats [Inoue, A. et al., 2005] and mice [Schiffelers, R.M. et al., 2005] . In both cases, this was achieved by silencing the tumor necrosis factor α (TNFα) gene. Collectively, these results suggest the potential feasibility of therapeutic intervention for treatment of rheumatoid and other locomotor diseases using EP.
Spleen -A few studies explored the in vivo gene electrotransfer into spleen, either after direct injection into the spleen or after intravenous administration of nucleic acids, in order to create a new tool to modulate the immunoinflammatory system [Tupin, E. et al., 2003] . The intrasplenic EP was found to be an efficient gene transfer method, for expressing secreted or intracellular proteins transiently for no more than 30 days. One remarkable fact is that transduced cells were still present in the spleen 30 days after electrotransfer, but they were also detected in extrasplenic locations.
Testis -The study of gene function in testis and sperm has been greatly assisted by transgenic mouse models. An alternative way of expressing transgenes in mouse testis has been developed that uses in vivo EP technique in conjunction with direct plasmid injection into testes to introduce transgenes into the male germ cells, method that could be used to create transgenic animals, to treat some types of infertility, to study the role of different genes during differentiation (such as using the iRNA as an inactivating tool [Shoji, M. et al., 2005] ), or for promoter characterization [Kirby, J.L. et al., 2004] . The transfer of plasmid-encoded erythropoietin to rat testes by in vivo by EP was proposed as a means to reduce the risk of the germ cell loss caused by cryptorchidism [Dobashi, M. et al., 2005a] . Older studies showed that after testicular injection and EP, plasmid is rapidly transferred to epididymal ducts and incorporated by ductal epithelial cells and epididymal spermatozoa [Sato, M. et al., 2002] . Longlasting GFP expression could be detected in the sperm cells even 2mon after EP in a hamster model [Hibbitt, O. et al., 2006] , without any evidence of significant long-term adverse effects on testicular integrity and sperm quality. In a yet different mouse model, male mice that received the procedure were mated with normal females, and the number of offspring did not differ significantly from normal controls [Umemoto, Y. et al., 2005] . [Kachi, S. et al., 2005] Eye (intravitreous)
Wistar rats 5 pulses x 2, 99ms, 12V/cm, 5min between pulses TE buffer Forcep-type electrodes The conditions, species and references of recent selected studies using EP in eye, liver, testis and spleen are summarized (Table 7) .
Constant Current Versus Constant Voltage
To better understand the process of electroporation, it is important to look at some simple equations. When a potential difference (voltage) is applied across the electrodes implanted in a tissue, it generates an electric field ("E"), which is the applied voltage ("V") divided by the distance ("d") between the electrodes: E = V / d.
The electric field intensity E has been a very important value when formulating electroporation protocols for the delivery of a drug or macromolecule into the cell of the subject. Accordingly, it is possible to calculate any electric field intensity for a variety of protocols by applying a pulse of predetermined voltage that is proportional to the distance between electrodes. The flow of electric charge (current) between electrodes is achieved by the buffer ions in the tissues, which can vary among tissues and patients. Furthermore, the flow of conducting ions can change between electrodes from the beginning of the electric pulse to the end of the electric pulse. When tissues have a small proportion conducting ions, resistance is increased, heat is generated and cells are killed. Ohm's law expresses the relationship between current ("I"), voltage ("V"), and resistance ("R"): R = V / I.
Heating is the product of the inter-electrode impedance (i.e. combination of resistance and reactance and is measured in ohms), and is proportional to the product of the current, voltage and pulse duration. Heating can also be expressed as the square of the current, and pulse duration ("t", time). For example, during electroporation the heating or power ("W", watts) generated in the supporting tissue can be represented by the following equation: W = I 2 Rt.
During pulses, specific tissue resistance may drop Khan, A.S. et al., 2005b] , and the same voltage which did not cause significant heating during the first pulse can burn the tissue during the second (the equation W=V 2 t/R illustrates this undesirable effect). Constant current EP prevents this overheating, but constantvoltage techniques do not take into account the individual and changing resistance of the tissue and can result in tissue damage, inflammation, and loss of plasmid expression. For this reason, recently we have used constant current EP, which we refer to as electrokinetic enhancement. Thus, we have used a software-driven constant-current electroporator denoted electrokinetic device (EKD device) (Table 1) to deliver plasmids to small and large animals [Brown, P.A. et al., 2004; Khan, A.S. et al., 2005b] . The most favorable conditions of electroporation were dependent on the individual tissue resistance, which varies by age and species (see below). We found that EPinduced tissue injury can be reduced or eliminated by applying optimal constant current instead of constant voltage. Tweezer-type electrodes [Shoji, M. et al., 2005] Indeed, this prevents tissue heating and cell death, and is most relevant to gene therapy in large animals.
Species Differences
Plasmid delivery with EP into the muscle is the best example for how species-specific differences impact the practical aspects of EP. Some recent studies systematically tested and identified a series of preferred conditions for plasmid delivery with EP [Khan, A.S. et al., 2005b; Wang, X.D. et al., 2005] , factors that impact level and duration of expression [Molnar, M.J. et al., 2004] and demonstrated that plasmid delivery did not intrinsically activate stress genes [Rubenstrunk, A. et al., 2004] . Mechanistic studies have shown that the degree of permeabilization of the muscle cells and muscle damage is dependent upon the electric field intensity, length of pulses, shape and type of electrodes, and cell size [Bureau, M.F. et al., 2004; Davalos, R.V. et al., 2003; Durieux, A.C. et al., 2004] . It has been long since established that characteristics of the skeletal muscle, such as muscle fiber diameter, collagen fiber content, interstitial fat, etc., are not similar in different animal species, with a clear difference between small mammals, such as rodents and larger species, such as pigs, nonhuman primates or humans. Two major areas have to be considered: 1) the adaptation of the electrodes and EP conditions to the size and location of the target organ (e.g., plate electrodes may be adapted for small rodents in a multitude of situations, but are less useful in larger animals or humans, with the exception of skin, surface tumors or eye EP; larger plasmid volumes and different formulations that impact EP conditions, etc.), and 2) the tissue impedance changes during each pulse, and it is different from tissue to tissue and species to species. Taking again the skeletal muscle as an example, very recent publications showed that generally rodent muscles exhibit higher impedance than rabbits, monkeys or pigs [Khan, A.S. et al., 2005b; , and younger animals have higher muscle impedance than older ones [Khan, A.S. et al., 2005b] . Also, tissue impedance upon EP decreases. If constant voltages are used; the current almost doubles during treatment, resulting in cell death, tissue damage and pain . Thus, despite intensive work to optimize EP conditions in rodents for pre-clinical experimentation, lately it became apparent that individual optimization of EP conditions is required for both small animal experimentation and large animal testing, the latter being essential for translation of this technology to human medicine.
Potential Hazards
Typically, after injection and EP, nucleic acids enter the target cells; plasmids reside in a episomal form; RNA and oligonucleotides exert their activity for a short period of time before being degraded and eliminated; thus, potential hazards such as integration have been studied for longer-lived molecules, i.e. plasmids, targeted to post-mitotic tissues, i.e. skeletal muscle.
Plasmids that have not been uptaken are rapidly destroyed by natural proteases [Bureau, M.F. et al., 2004; Maeda, S. et al., 2004] . For instance, at 24h post-injection, an excessively low quantity of the injected plasmid remains at the injected site, as all the plasmid that is not momentarily uptaken by the muscle fibers is destroyed by natural mechanisms. The use of plasmids for DNA vaccines and for potential treatment of disease has stimulated great interest in the molecular and physiological processes by which plasmid is removed from site of administration, particularly from muscle. Barry et al. [Barry, M.E. et al., 1999] used a comprehensive set of biomolecular tools to demonstrate that any plasmid is rapidly degraded in the muscle by endonucleases, such that about 1% of the initial dose remains at 90min. Moreover, DNA degradation proceeds until fragments of 25 to 125 base pairs are generated, thus precluding any further expression of the nucleic acid . Insight into a plausible mechanism for long-term retention in muscle comes from cell culture experiments in which DNA plasmids were microinjected into either the cytoplasm or into the nucleus of cells. Lechardeur et al. [Lechardeur, D. et al., 1999] found that plasmid DNA disappeared from the cytoplasm with an apparent half-life of 50 to 90 min. Comparison of expression upon nuclear and cytoplasmic injection of plasmid DNA showed that only about 0.1% of the cytoplasmic plasmid DNA enters the nucleus. Pollard et al. [Pollard, H. et al., 2001] confirmed this finding and demonstrated that there was no significant degradation of plasmid DNA in the nucleus for the duration of the experiment.
The safety of DNA administered by injection into the muscle has been evaluated in humans and in many animal species [Bloquel, C. et al., 2004b; Quezada, A. et al., 2004; Thioudellet, C. et al., 2002] . All results indicate that plasmid DNA is generally well tolerated and show there are no serious adverse effects associated with either plasmid backbones or different active expression cassettes. Some adverse effects, however, include muscle contraction at the time of current application, and local pain which is usually not severe. The studies on human subjects reported to date, using fundamentally different active expression cassettes in plasmid DNA delivered in different doses, show no serious adverse effects [Baumgartner, I. et al., 1998; Isner, J.M. et al., 2001; Romero, N.B. et al., 2002] . Adverse effects in treated subjects may still occur and are related to the transgene product.
One historical concern was that, after injection, the DNA would integrate into the recipient host's chromosomes leading to mutagenesis and potentially insertion carcinogenesis. Animal studies involving plasmid DNA injections have shown that mutations from a potential integration event would be extremely infrequent, about 3000 times lower than the spontaneous mutation rate for mammalian genomes. Multiple studies indicate that plasmid-based vaccines and DNA fragments injected intramuscularly integrate extremely infrequently into the host genome, even when there is substantial homology between plasmid and genomic sequences [Ledwith, B.J. et al., 2000b; Ledwith, B.J. et al., 2000a; Manam, S. et al., 2000] . Using a quantitative gel-purification assay for integration, EP under conditions that induce severe muscle damage in mice was found to markedly increase the level of plasmid associated with high-molecular-weight genomic DNA [Wang, Z. et al., 2004] . Even in this extreme situation, an unlikely integration event would occur in no more than 0.5% of cells, an exceptionally low number, contained within the EP site. The translation of these results for larger animals is unclear. For instance, a pig muscle that weighs, on average, 400gm, contains approximately 600,000 fibers [Nissen, P.M. et al., 2004] . Even treating a pig muscle, the volume of the electroporated region of the muscle to be the most 6cm 3 and to contain no more than 1.5% of the total number of fibers of the target muscle [Khan, A.S. et al., 2003b] . An 80 to 100kg body contains an estimated 10 to 100 trillion cells, thus the frequency of integration would be 4.5x10 -12 to 4.5x10 -13 . Using a worst-case calculation, the integration frequency at the EP site is still below the spontaneous rate of gene-inactivating mutations [Wang, Z. et al., 2004] . Milder, more currently used conditions have not been tested or reported. Furthermore, the risk and benefits should be compared to those of viral vectors [Barzon, L. et al., 2005; Maguire-Zeiss, K.A. et al., 2004] .
THERAPEUTIC USES OF IN VIVO ELECTRO-PORATION
Gene Therapy of Lupus with Cytokine Inhibitors
Regulatory cytokines such as TGF-β1, IL-4 and IL-10 can protect against several autoimmune or inflammatory diseases, including lupus, type 1 diabetes (T1D), experimental autoimmune encephalomyelitis (EAE), and various forms of arthritis. The in vivo delivery of these cytokines can be performed by both viral and nonviral gene therapy methods, as we have previously reviewed [Piccirillo, C.A. et al., 2005; Piccirillo, C.A. et al., 2003; Prud'homme, G.J., 2000; Prud'homme, G.J. et al., 2001b; Prud'homme, G.J. et al., 2001a] . However, cytokines have pleiotropic effects, and their administration can be associated with toxicity and other undesirable effects. On the other hand, cytokine inhibitors (usually antibodies or soluble cytokine receptors) are advantageously non-toxic and often long-lived in body fluids, compared with most cytokines. Most gene therapy studies of cytokine inhibitors have been carried out with viral vectors, and there is less experience with nonviral methods. However, we and others have shown that the plasmid-based transfer of cDNA encoding these molecules protects against several autoimmune diseases. For our studies, we constructed an expression plasmid encoding an interferon γ receptor/immunoglobulin G1-Fc (IFN-γR/IgG1-Fc) fusion protein . The relevant murine cDNA segments were inserted into the plasmid VR1255 (Vical Inc., San Diego, CA), which is exceptionally well expressed in muscle tissue [Hartikka, J. et al., 1996] . It has a CMV immediate-early enhancer promoter (IE-EP), CMV intron A, and a rabbit β-globin transcriptional terminator. IFNγR/IgG1-Fc encoded by this vector was secreted as a homodimer and neutralized IFNγ in vitro and in vivo. I.m. injections (100µg naked DNA/muscle into 2 muscles, administered twice) of the IFNγR/IgG1-Fc plasmid in normal mice resulted in IFNγR/IgG1-Fc serum levels exceeding 100ng/ml for months after treatment. Higher levels (>200ng/ml) were produced by repeated DNA injections. Interestingly, EP was not required to achieve these levels in normal mice, but proved essential in lupus-prone mice, as detailed below. We hypothesize that the high-level and longterm expression of this vector (compared with many other plasmid vectors we have investigated) is related to the neutralization of IFN-γ, because this cytokine can shut down transcription driven by CMV IE-EP elements. There may also be a more general anti-inflammatory effect, which contributes to vector expression. It should be noted however, that promoter shut down can be prevented or minimized by employing newer vectors (described previously in this manuscript) which have muscle-specific promoters such as SPc5-12. These promoters are capable of very long expression (e.g., up to 48 months in cattle), and do not appear to be cytokine sensitive.
There are numerous cytokine abnormalities in lupus, but increased levels of IFNγ, as well as IFNα/β species, in serum, lymphoid organs and inflamed tissues are most important Mageed, R.A. et al., 2003; . These are inflammatory cytokines that can contribute to disease activity in many ways. Notably, the production of IFNγ is extraordinarily high in MRL-Fas lpr lupus-prone mice [Lawson, B.R. et al., 2000; Prud'homme, G.J. et al., 1995] . Therefore, it was of interest to determine if IFN-γ could be blocked by a gene therapy approach. We inoculated an IFN-γR/IgG1-Fc plasmid into lupus-prone and observed low level expression compared with a previous study in nonobese diabetic (NOD) and CD1 mice with the same vector. However, in view of the high IFN-γ levels, residual IFN-γ was probably shutting down the vector's CMV enhancer/promoter. To improve these results, in vivo EP was applied at the site of DNA injection: 6 pulses applied with internal needle electrodes, at 200V/cm, 50msec duration and 1sec apart (in more recent studies we have applied 8 pulses, 200V/cm, 20msec, using external caliper electrodes). The serum IFN-γR/IgG1-Fc levels (<10ng/ml without EP) exceeded 100ng/ml and serum levels of IFN-γ markedly declined [Lawson, B.R. et al., 2000] . This gene therapy protected MRL-Fas lpr mice from early death and reduced autoantibody titers, renal disease and histological markers of systemic lupus erythematosus (SLE)-like disease. Most importantly, when treatment was started in 4-monthold diseased mice, survival was extended beyond expectations, with all the mice surviving at 14mo of age, compared with none in the control group. Remarkably, disease severity was reduced or even suppressed in the treated group. Other groups have attempted to neutralize IFN-γ in mouse lupus models using polyclonal and monoclonal antibodies (mAbs), as well as soluble IFN-γR, but these methods were not as effective and have limitations. Large amounts of mAbs have to be administered and do not necessarily produce sufficient concentrations in tissues to be effective. There is also the possibility that mAbs will be neutralized by the host immune response, because of reactivity to either allogeneic, xenogeneic or idiotypic antigenic determinants. In the case of soluble recombinant receptors (without Fc conjugation), rapid turnover may reduce their effectiveness.
The IFN-γR/IgG1-Fc fusion protein produced in these studies consists of segments of endogenous murine proteins. We have not observed antibodies reactive with these proteins in treated mice, despite repeated injections of plasmid vector over several weeks. In this respect, it is abundantly clear that plasmids that do not encode immunogenic proteins, or plasmids injected into immunodeficient severe combined immunodeficient (SCID) mice, are expressed for much longer periods.
The inclusion of an immunoglobulin Fc segment to a therapeutic protein is not always essential, but may confer significant advantages. The Fc portion simplifies purification of the recombinant protein by affinity chromatography and, primarily because of larger size, increases considerably the half-life of small proteins in body fluids. For instance, the half-life of the truncated IFN-γR is quite short compared with an IFN-γR/Fc fusion protein [Kurschner, C. et al., 1992] . Also, dimers are likely to have a higher avidity for their ligand, as is clearly the case with the IFN-γ receptor. Finally, although this remains to be demonstrated, the Fc segment may bind to inhibitory Fc receptors (FcγRIIB) of B lymphocytes and suppress production of neutralizing antibodies, since a similar inhibitory effect has been observed in allergic effector cells in models of allergy [Kraft, S. et al., 2005] .
Systemic Delivery of Cytokine Inhibitors in Arthritis
As mentioned previously, therapeutic genes can be directly delivered into the joint, but frequently systemic therapy has been applied. IL-1 receptor antagonist (IL-1Ra) is an endogenous protein that can prevent the binding of IL-1 to its cell-membrane receptors. IL-1Ra has shown effectiveness in the therapy of arthritis and is a promising molecule for gene therapy. However, most studies have been conducted with viral vectors. Jeong et al. studied the effects of EP after intramuscular injection of a human IL-1Ra plasmid, in a murine model of CIA. They reported human IL-1Ra expression for > 20 days. CIA was significantly inhibited and histological examination of knee joints revealed that arthritis was prevented. The levels of mouse IL-1 β and IL-12 in paws were significantly lower in the group treated with IL-1Ra than those in the control group.
Other studies utilizing intramuscular plasmid-based electrogene transfer [Bloquel, C. et al., 2004a; Gould, D.J. et al., 2004; Kim, J.M. et al., 2003] have shown the effectiveness of soluble TNF-receptor cDNA in CIA. As expected, in vivo EP greatly increases the effectiveness of these vectors. In one study, the inhibition of established CIA was performed with a doxycycline regulated plasmid [Gould, D.J. et al., 2004] . Protection against CIA has also been achieved by electrogene transfer of IL-4 [Kageyama, Y. et al., 2004] and IL-10 genes, for systemic delivery of these cytokines [Miyata, M. et al., 2000; Saidenberg-Kermanac'h, N. et al., 2003 ]. These studies demonstrate that nonviral gene therapy can be effective against arthritis, at least when gene transfer is enhanced by EP.
Cytokine Inhibitors in Other Autoimmune Diseases
The transfer of cDNA encoding cytokine inhibitors protects against several autoimmune diseases [Piccirillo, C.A. et al., 2005; Prud'homme, G.J. et al., 2001b] . IL-12 and IFN-γ are usually detrimental in autoimmune diseases and, consequently, their neutralization is likely to be protective. These two cytokines are functionally related, since IL-12 induces IFN-γ production by T cells and NK cells, while IFN-γ mediates or augments many of the effects initiated by IL-12. The neutralization of IFN-γ with mAbs or soluble receptors prevents NOD-mouse diabetes [Campbell, I.L. et al., 1991; as well as diabetes induced by administration of multiple low-dose streptozotocin STZ (MDSD) in other strains [Kurschner, C. et al., 1992] . Cyclophosphamide (CYP) greatly accelerates disease in NOD mice, and the CYP-and STZ-induced diseases are both associated with a burst of systemic and intra-islet IFN-γ release. Indeed, we observed that i.m. administration of an IFN-γ expression plasmid accelerated disease in NOD mice (but a TGF-β1 plasmid was protective) [Piccirillo, C.A. et al., 1998 ], and others found that non-diabetes-prone transgenic mice expressing IFN-γ in their islets developed insulitis/diabetes associated with a loss of tolerance to islet antigens [Sarvetnick, N. et al., 1990] . In vivo, administration of our IFN-γR/IgG1-Fc vector almost completely blocked the systemic IFN-γ activity induced by either STZ (CD-1 or C57BL/6 mice) or CYP (NOD mice). Moreover, this plasmid was protective in either natural or drug-induced models of autoimmune diabetes in agreement with the postulated pathogenic role of IFN-γ. In each case, therapy reduced the severity insulitis and the frequency of diabetes which is secondary to this lesion. It should be noted, however, that this anti-cytokine therapy was more effective in the induced models of diabetes (STZ of CYP), presumably because IFN-γ plays a more important role in the pathogenesis of these diseases. Electroporation was not required for the therapy of these murine models of diabetes, but it can be anticipated that it would be in larger animals with similar disease.
Features of DNA Vaccination and Its Advantages
DNA vaccination has been intensely studied as a means of generating immunity against the antigens of infectious agents or tumors. This is due to the simplicity, versatility, and safety of the method. In the vast majority of cases, DNA has been delivered in the form of an expression plasmid, either naked or complexed to other molecules, although other types of vectors can be used.
The features of these vaccines have been extensively reviewed [Barouch, D.H. et al., 2004; Barouch, D.H., 2006; Calarota, S.A. et al., 2004; Gurunathan, S. et al., 2000; Howarth, M. et al., 2004; Leifert, J.A. et al., 2004; Prud'homme, G. et al., 2005; Prud'homme, G.J., 2005] and will only be briefly mentioned here. Plasmids can be delivered by intramuscular (i.m.), intradermal (i.d.)/epidermal, or subcutaneous (s.c.) injections, or by oral (e.g., with bacterial carrier), pulmonary (aerosols), or other routes (e.g., vaginal). Plasmid-encoded antigen is presented by bone marrowderived antigen-presenting cells (APCs), which are most likely dendritic cells (DCs). There are two documented mechanisms of antigen uptake by the APCs, i.e., direct transfection of the APCs and synthesis of the antigen, or uptake of the antigen from other transfected cells (cross presentation).
Compared to other methods, the advantage of DNA vaccination is that delivery of the antigen gene can easily be coupled to the delivery of any of a number of genes that modify the immune response. Moreover, antigen presentation occurs through both the MHC class I or class II restricted pathways, and all arms of the immune response are activated, i.e., T-helper (Th) cells, CTLs and humoral immunity. Notably, DNA vaccination is more potent at inducing CTLs compared to many other vaccine formulations.
An important component of the plasmid is the presence of unmethylated CpG-ISS, that can activate innate immunity by binding to toll-like receptor 9 (TLR9) located in endocytic vesicles of APCs [Klinman, D.M., 2004; Krieg, A.M., 2002; Vollmer, J. et al., 2004] . CpG motifs appear to act as adjuvants in DNA vaccination but, interestingly, they are not essential because TLR9-knockout mice still respond to these vaccines [Spies, B. et al., 2003] . Engagement of TLR9 triggers a cell signaling cascade involving sequentially myeloid differentiation primary response gene 88 (MyD88), IL-1 receptor activated kinase (IRAK), TNF receptor (TNFR)-associated factor 6 (TRAF6), and activation of nuclear factor kappaB (NF-κB) [Klinman, D.M., 2004] . Cells that express TLR9, which include plasmacytoid dendritic cells (PDCs) and B cells, produce IFN-α/β, inflammatory cytokines such as IL-12, and chemokines.
Enhancement of DNA Vaccines by Electroporation
DNA vaccination has been effective in rodents, but results have been less impressive in large animals and humans. Consequently, many approaches have been investigated to improve these vaccines (reviewed in [Prud'homme, G.J., 2005]), and one of the most effective has been in vivo EP. Indeed, the application of EP, regardless of the site of injection, should favor the transfection of a greater variety of cells, including APCs. As an additional mechanism, mild tissue damage as may be induced by EP could provoke an influx of APCs, induce danger signals (e.g., inflammatory mediators and chemokines), and enhance the release of antigen from injured cells, thereby increasing antigen presentation.
The work of Gronevik et al. , for example, supports the view that tissue injury is relevant. These authors found that in mice immunized against human secreted alkaline phosphatase (SEAP) by combined intramuscular DNA inoculation and EP, the highest levels of antibody production occurred in mice with the most muscle damage. DNA-transfected muscle fibers were reduced in numbers between days 7 to 14, and antigen-expressing cells were surrounded by mononuclear cells. It appears that myocytes are first damaged by EP, and subsequently, by an immune response against the antigen they carry. Induced immunity appears to inhibit or terminate vector expression. Furthermore, they report that optimal DNA vaccination requires different electrical parameters than long-term gene expression. Interestingly, for short-term vector expression and/or DNA vaccination, they found that unipolar electrical pulses are more effective than bipolar pulses, possibly because this promotes unidirectional DNA movement. However, the results of these and similar vaccination studies must be interpreted with caution, because many factors (other than tissue injury) are relevant, such as the site of injection, choice of plasmid, electrical parameters, antigen load, coadministration of immunostimulatory agents, and species. The properties of the antigen (e.g., secreted versus cytoplasmic, immunogenicity and half-life) can also markedly affect the outcome.
Electroporation has improved DNA vaccination in several species including mice, guinea pigs, rabbits, pigs, farm ruminants, and rhesus macaques. Moreover, this has been observed against quite a wide variety of antigens, which were either delivered intramuscularly or (less frequently) applied to the skin. Only a few examples will be mentioned here, but more information can be found in other publications [Babiuk, L.A. et al., 2003; Otten, G. et al., 2004; Prud'homme, G.J., 2005; Scheerlinck, J.P. et al., 2004; Tollefsen, S. et al., 2003; van Drunen Littel-van den Hurk et al., 2004; Wu, C.J. et al., 2004; Zhao, Y.G. et al., 2005] . For instance, in rhesus macaques, Otten et al. [Otten, G. et al., 2004] found that EP enhanced DNA vaccination to both the Gag and Env proteins of HIV. There were improved antibody titers, as well as increased numbers of IFN-γ-positive CD4 T-helper (Th) cells and CTLs. All these responses occurred sooner and were stronger in the electroporated primates. Similarly, in this species, Zhao et al. [Zhao, Y.G. et al., 2005] administered EP to enhance DNA vaccination against an hepatitis B virus (HBV) antigen; however, they included an adjuvant plasmid encoding both human IL-2 and IFN-γ. These authors showed that EP greatly augmented antibody responses and antigen-stimulated IFN-γ producing T-cell responses. Interestingly, they could modify the antibody response by changing electro-pulse parameters. Overall the results of these studies, particularly in primates, are highly encouraging for the future application of this technology in humans.
In situations where therapeutic vaccination is contemplated, notably in AIDS or cancer patients, it is necessary to treat immune impaired subjects. Interestingly, EP has enhanced DNA vaccination sufficiently to stimulate generation of CTLs in knockout mice lacking CD4 cells (MHC class II knockout) [Dayball, K. et al., 2003] . This is a situation where responses are usually quite weak and is of interest for vaccination of patients with CD4+ cell deficiency.
Prime-Boost Strategies
DNA vaccination can be applied alone, or in combination with other vaccination methods. It is too early to draw definitive conclusions but, at least in humans, it appears that a combination of methods is more effective than plasmid inoculation alone. Thus, plasmid inoculation can be used to initiate (prime) the response, which can then be boosted by another approach, such as a viral genetic vaccine or an antigen/adjuvant mixture (heterologous prime-boost vaccination). Indeed, recent clinical trials indicate that heterologous prime-boost strategies can provoke strong immune responses [McConkey, S.J. et al., 2003; Vuola, J.M. et al., 2005; . However, to our knowledge, all clinical trials were performed without EP, and much more work is required to establish optimal DNA vaccination protocols in humans. Thus, it is not excluded that when EP is applied, priming and boosting with plasmids alone will be effective. Indeed, in a preclinical model, EP-enhanced homologous prime-boosting with plasmids only was effective at inducing both CTLs and antibodies against a tumor antigen [Buchan, S. et al., 2005] .
Breaking Immunologic Tolerance with Plasmid DNA
A remarkable feature of DNA vaccines is that they can be employed to break tolerance to self or transgenic "neoself" antigens. DNA vaccination has been exploited as a means of inducing organ-specific autoimmunity in animals. Transgenic mice expressing lymphocytic choriomeningitis virus nucleoprotein (NP) under the control of a liver-specific promoter developed liver injury when vaccinated with plasmids expressing NP as an intracellular or a secretory protein [Djilali-Saiah, I. et al., 2002] . Coinjection of an IL-12 bicistronic plasmid that we constructed [Song, K. et al., 2000a; Song, K. et al., 2000b] with an NP plasmid increased T-cell activation and liver injury. Autoimmunity has also been induced against the thyroid gland in outbred NMRI mice, by vaccination with a plasmid encoding the human thyrotropin receptor (TSHr) [Costagliola, S. et al., 2000] . The mice produced antibodies reactive to TSHr, and some showed signs of hyperthyroidism including elevated total T4 and suppressed TSH levels. The mice developed goiters with extensive lymphocytic infiltration and displayed ocular signs similar to those of Graves' disease.
It is of some concern that transfected muscle cells may be attacked and injured by the immune system following DNA vaccination against foreign antigens, and this has been reported [Davis, H.L. et al., 1997; Gurunathan, S. et al., 2000] . A related concern is the production of pathogenic anti-DNA antibodies, potentially induced by plasmid DNA and its ISS motifs, but the risk appears relatively small. B cells have mechanisms which prevent autoantibody production in response to CpG stimulation [Rui, L. et al., 2003] , although this tolerance can be broken [Tran, T.T. et al., 2003] . In lupus-prone mice, anti-dsDNA antibodies titers are increased by DNA vaccination. However, there have been contradictory reports on the effects on disease. Some authors have reported that injection of bacterial DNA (carrying CpG-ISS) in lupus-prone mice reduced the severity of disease, or in some cases had no effect [Gilkeson, G.S. et al., 1996; Pisetsky, D.S., 2000] . Other authors have reported that stimulation through TLR9 induces progression of renal disease in both MRL-Fas lpr [Anders, H.J. et al., 2004] and NZB x NZWF1 [Hasegawa, K. et al., 2003 ] lupus-prone mice. Recently, Wu and Peng [Wu, X. et al., 2006] reported that TLR9-deficient mice (unable to respond to CpG) of both the MRL/+ (unmutated Fas) and the MRL-Fas lpr (mutated Fas) backgrounds developed more severe lupus, as determined by anti-DNA and rheumatoid factor autoantibodies, total serum Ig isotypes, lymphadenopathy, inflammatory infiltrates in the salivary gland and kidney, proteinuria, and mortality, in comparison with their TLR9-sufficient littermates. Regulatory T cells from TLR9-deficient animals were impaired in their activity. Based on this, they conclude that TLR9 stimulation is protective. Evidently, the effects of CpG motifs on lupus should be analyzed further, and special caution should be exercised in administering CpG-bearing plasmids to patients with autoimmune diseases. Although this has not been reported, the application of EP might accentuate some of the negative effects noted above.
Potential Advantages of DNA Vaccines in Overcoming Tumor Resistance to Immunity
The ability of DNA vaccines to break tolerance has found applications in tumor immunology, because most tumorassociated antigens (TAAs) are poorly immunogenic self molecules. In this situation, several studies have demonstrated the effectiveness of EP, for example, in vaccination against melanoma-associated antigens, HER2/neu (c-ErB2) and carcinoembryonic antigen (CEA) [Prud'homme, G.J., 2005] . We will discuss the latter two cases in more detail.
DNA Vaccination Against Her-2/neu
Considerable overexpression of HER-2/neu, usually due to gene amplification, has been observed frequently in malignant tumors of the breast, ovary, pancreas, colon, lung and other tissues, and generally correlates with a poor prognosis [Baxevanis, C.N. et al., 2004] . HER-2/neu is normally expressed at low levels in a variety of human tissues (skin, digestive tract epithelium, breast, ovary, hepatocytes, and alveoli), such that normal individuals are immunologically tolerant. Therapy with humanized anti-HER-2/neu mAbs (Herceptin) has shown beneficial effects in some breast cancer patients [Baxevanis, C.N. et al., 2004] , and there is considerable interest in developing a vaccine against this molecule.
Transgenic mice bearing either an activated form of rat neu or the wild-type proto-oncogene, under the transcriptional control of the mouse mammary tumor virus (MMTV) promoter-enhancer, frequently develop mammary carcinomas similar to the human disease, with the activated gene inducing tumors earlier [Amici, A. et al., 2000; Di, C.E. et al., 2001; Piechocki, M.P. et al., 2003; . Many of the tumor-bearing transgenic mice develop metastases in the lung. Amici et al. [Amici, A. et al. , 1998 ] developed a DNA vaccine against full-length activated rat neu (neuNT, differing from wild-type neu by one amino acid). This vaccine protects FVB/neuNT (strain 233) transgenic mice bearing neuNT. Vaccination induced a Th1 response to neu, associated with hemorrhagic necrosis of established cancer nests. Subsequently, Amici et al. [Amici, A. et al., 2000] administered plasmids encoding the full-length rat neu oncogene (pCMV-neuNT), the extracellular domain (pCMV-ECD), or the extracellular and transmembrane domains (pCMV-ECD-TM). pCMV-ECD-TM induced the best protection, but all plasmids were equally effective when coinjected with an IL-12 plasmid. Other authors have reported similar findings. Furthermore, numerous methods have been found to improve these vaccines (reviewed in [Prud'homme, G.J., 2005]) , and elecrotroporation appears to be one of the most effective [Buchan, S. et al., 2005; Quaglino, E. et al., 2004; Smorlesi, A. et al., 2005; Spadaro, M. et al., 2005] .
Of note, Quaglino et al. [Quaglino, E. et al., 2004] reported that i.m. vaccination of BALB/c neu transgenic (BALB-neuNT) mice with DNA plasmids coding for the extracellular and transmembrane domains of the protein product of the HER-2/neu oncogene, started when mice already display multifocal in situ carcinomas, delayed but did not prevent tumor growth, unless EP was applied. This is not surprising, because BALB/c-neuNT female mice have one of the most aggressive progressions of HER-2/neu carcinogenesis. However, elimination of mammary neoplastic lesions and complete protection were achieved when vaccination was repeatedly enhanced by EP, at intervals of 10wk. Remarkably, all mice that received four DNA EP courses (beginning at weeks 10 to 12) were tumor free at one year of age. Using gene knockout mice, they demonstrated that tumor clearance depended on a combination of antibodies and IFN-γ-producing T cells. The elimination of in situ carcino-mas was associated with a massive infiltration of IFN-γ-producing T cells, which appeared to interact with tumor cells. DNA-electroporated mice terminated at week 52 were free of autoimmune lesions in the heart, kidney, and liver, even though the induced anti-neu antibodies cross-reacted with mouse endogenous erbB2. Thus, DNA vaccination eliminated existing multifocal neoplasms, without inducing autoimmunity.
DNA Vaccination Against Carcinoembryonic Antigen (CEA)
CEA is a 180 kD membrane-bound glycoprotein that is a well-defined TAA, and a potential target of immunotherapy (reviewed in [Berinstein, N.L., 2002] ). Conry et al. [Conry, R.M. et al., 1995b; Conry, R.M. et al., 1995a; Conry, R.M. et al., 1996] first demonstrated that DNA vaccination against this antigen was feasible in mice. We found that i.m. injections of a plasmid encoding human CEA elicited both humoral and cellular immune responses, but only delayed the growth of transplanted syngeneic CEA+ tumor cells [Song, K. et al., 2000a; Song, K. et al., 2000b] . Coinjection of the CEA vector with a vector encoding either IFN-γ or IL-12 (bicistronic p35/p40) promoted a Th1 response, anti-CEA CTL activity and resulted in up to 80% tumor-free survival following a challenge. In contrast, coinjection of the CEA vector with an IL-4 vector produced a Th2 response and a reduction in CTL activity. Resistance to a tumor challenge was also decreased.
We described a non-viral intramuscular gene transfer method to deliver the immunostimulatory B7.1/IgG1-Fc fusion protein [Zhou, Z.F. et al., 2003] , and ameliorate vaccinaton to CEA. Gene transfer was greatly enhanced by EP. Serum levels reached up to 1µg/ml with considerable length of expression and without apparent systemic adverse effects. Lymphocytes from mice co-injected with soluble B7-1/IgG1-Fc-and CEA-encoding plasmids showed significantly elevated CEA-stimulated proliferation, cytokine production, and CTL activity. These mice gained significant protection against a CEA+ transplanted tumor, in terms of reduced tumor incidence and growth. The effects were superior when soluble B7-1/IgG1-Fc was expressed as compared to membrane-bound wild-type B7-1. It is important to note that the plasmid encoding B7-1/IgG1-Fc did not have to be injected at the same site as the antigen-encoding plasmid to exert its adjuvant effect, indicating that circulating protein is sufficient. This differs from IL-12 and granulocytemacrophage colony-stimulating factor (GM-CSF) plasmids, which are usually only effective when injected at the same site as the antigen. Muscle histopathology revealed minimal damage to CEA cDNA-injected muscles. In the clinical situation, to ameliorate DNA vaccination, it would probably be feasible to administer B7/IgG-Fc either by gene transfer or as a soluble protein.
Our studies in mice reveal that cytokine-encoding plasmids injected intramuscularly can induce release of cytokines into the circulation [Peretz, Y. et al., 2002; Song, K. et al., 2000a; Song, K. et al., 2000b] . Even though circulating concentrations are low, this could have undesirable effects. Indeed, inflammatory cytokines such as IL-12 and IFN-γ are highly toxic. To eliminate this concern, we demonstrated that DNA co-vaccination with membrane-bound or membrane-bound IL-12 (mbIL-12) both enhance anti-CEA immunity, as detected by in vitro and in vivo assays [Chakrabarti, R. et al., 2004] . As in our other studies, the application of EP was required for optimum results.
B7, CD28 and CTLA-4 in DNA Vaccination Against Tumors
CD28 is a T-cell costimulatory molecule that plays a critical role in initiating immune responses following DNA vaccination by binding to either B7-1 or B7-2, which are expressed by APCs. This has been clearly confirmed in studies in CD28 gene knockout mice [Horspool, J.H. et al., 1998 ]. B7-1/IgG-Fc is thought to exert its immunostimulatory effect by binding to this molecule. On the other hand, CTLA-4 is a negative regulatory molecule also binding B7-1 and B7-2 that antagonizes CD28 costimulation and downregulates immunity against tumors. When combined with vaccination, CTLA-4 blockade with monoclonal antibodies is a powerful way to enhance immunity against tumor antigens, in both mice and humans [Egen, J.G. et al., 2002; Prud'homme, G.J., 2004] .
There have been few studies of CTLA-4 function relative to DNA vaccines. Recently, we found that DNA vaccination against CEA is stimulated by codelivery of cDNA encoding B7-1wa/Ig fusion protein and application of EP [Chakrabarti, R. et al., 2005] . B7-1wa is a mutated murine B7-1 molecule that binds to CTLA-4, but has lost the ability to bind to CD28. Because CD28 is not engaged, we postulate that B7-1wa/Ig interrupts negative signals generated by CTLA-4, and we have in vitro evidence to support this hypothesis. Moreover, because B7-1/IgG-Fc binds to both CD28 and CTLA-4 it seems likely that part of its effect also depends on the masking of CTLA-4.
DNA Vaccination for Type 1 Diabetes
Although DNA vaccines are usually immunostimulatory, inducing immunity against foreign or even self antigens (especially of tumors), they have protected against either experimental autoimmune encephalomyelitis (EAE), T1D or other forms of autoimmunity [Prud'homme, G.J., 2003] [ Prud'homme, G. et al., 2005] . However, both beneficial and detrimental effects have occurred for reasons that were not elucidated [Prud'homme, G. et al., 2005] . The relevance of immunostimulatory CpG motifs carried by plasmids in these models is unclear, but in some cases they have been (paradoxically) protective. NOD mice spontaneously develop T1D, and this is clearly a T-cell dependent autoimmune disease. The autoimmune response is directed against several antigens expressed by pancreatic beta cells, but of these insulin (and its precursor peptides) and glutamic acid decarboxylase 65 (GAD65) are the best studied. We and others have performed studies to determine whether DNA vaccination against these islet antigens could be protective [Glinka, Y. et al., 2003; Prud'homme, G.J. et al., 2002; Prud'homme, G.J., 2003] . We found that this could be effective, especially if the negative regulatory molecule CTLA-4 was engaged at the time of vaccination. Preliminary studies showed that the application of in vivo EP increases the effectiveness of antiislet antigen DNA vaccines, and all our studies outlined below in sections 6.6.1 and 6.6.2. were performed with in vivo EP.
Engaging CTLA-4 to Attenuate Autoimmune Responses
As noted previously, B7-1wa selectively binds to CTLA-4. We observed that DNA covaccination with B7-1wa cDNA blocked induction of immunity against a xenoantigen and reduced ongoing autoimmune responses against insulin in NOD mice [Prud'homme, G.J. et al., 2002] . Note that in this case B7-1wa is a membrane-bound molecule that can engage CTLA-4 and promote negative signaling, unlike B7-1wa/IgG-Fc (used in our cancer study) that is soluble and appears to block CTLA-4 negative signaling. The spleen cells of mice injected with either blank, B7-1 or B7-1wa plasmids responded equally well to insulin. In contrast, the spleen cells of NOD mice inoculated with a vector encoding both B7-1wa and preproinsulin (PPIns) had essentially no response to insulin in vitro. Both IFN-γ and IL-4 secretion were severely depressed. The response to GAD65 was not significantly altered, suggesting antigen specificity of tolerance induction. Our initial studies suggested that T cells might be anergic, but in more recent studies we identified protective regulatory T cells, as outlined below.
Induction of Regulatory T cells (Tr) in NOD Mice by DNA Vaccination
Natural Tr cells differentiate in the thymus and have a CD4+CD25+Foxp3+ phenotype [Piccirillo, C.A. et al., 2004; Sakaguchi, S., 2005] , but it is clear that other types of Tr cells can be generated in the periphery. Our initial studies of DNA vaccination in NOD mice were performed with preproinsulin (PPIns) as a target antigen, but subsequently we employed a PPIns/Glutamic acid decarboxylase 65 (GAD65) fusion (Ins-GAD) construct as the target antigen to introduce a larger number of autoantigenic target epitopes. DNA covaccination with Ins-GAD and B7-1wa (in contrast to other groups) consistently generated protective Tr cells, and markedly ameliorated disease [Y. Glinka, Y. Chang and G. J. Prud'homme; manuscript submitted]. Thus, the incidence of diabetes in this group was only about 12% compared to > 60% in unmanipulated mice, and this a result superior to all our previous vaccination studies.
We examined the response of lymphocytes from vaccinated mice both in vitro and in vivo. Adoptive transfer of T cells from vaccinated mice, injected with or without diabetogenic lymphocytes obtained from diabetic mice, revealed that the T cells of vaccinated mice could not transfer disease in NOD-SCID mice, and could significantly delay disease induced by the diabetogenic lymphocytes. Thus, the T cells of Ins-GAD/B7-1wa vaccinated mice exerted a regulatory effect in vivo. We further fractionated the protective T cells into CD4+CD25+, CD4+CD25-and CD8+ subpopulations and repeated the experiments. We found that both CD4+CD25+ and CD4+CD25-T cells were protective, whereas CD8+ cell exerted no beneficial effect. The regulatory T cells appear to suppress autoimmunity, at least in part, by producing transforming growth factor beta (TGF-β).
SPECIAL APPLICATIONS IN TYPE 1 OR 2 DIABETES MELLITUS 7.1. Insulin Gene Therapy
There has been considerable interest in transplanting genetically engineered cells capable of producing insulin for the treatment of insulin-dependent diabetes or, alternatively, in using somatic gene therapy to supply insulin. Unfortunately, it has not been possible to design non-endocrine cells that respond physiologically to glucose. However, continuous low-level (or basal) production of insulin could be beneficial in type 1 or 2 diabetic patients, provided hypoglycemia was not induced. We studied a muscle-based gene therapy approach to achieve this in mice ]. This required engineering proinsulin for processing by nonendocrine cells. The maturation process of insulin requires the action of two endopeptidases proprotein convertase (PC). The PC2 and the PC1 or 3 (PC1/3) are specifically expressed in the beta cells of the islets of Langerhans and some neuroendocrine cells. In nonendocrine cells, similar processing can be accomplished by adding furin cleavage sites [Gros, L. et al., 1997] .
We applied our therapy to STZ-induced diabetic mice . This required codelivery of two plasmids, one encoding a furin-cleavable insulin and the other furin. Insulin was further mutated to increase its activity, and in vivo EP was used to amplify gene transfer. With this approach, we were able to demonstrate partial processing of proinsulin to the mature form, and release of sufficient active insulin to prevent hyperglycemia. Our preliminary experiments had revealed that without EP and furin gene transfer hyperglycemia could not be reduced under otherwise similar conditions (unpublished observations). However, with EP, our therapy resulted in protection against hyperglycemia and a marked increase in plasma levels of proinsulin, mature insulin and free C-peptide. Other authors have also reported on nonviral muscle-based insulin gene therapy [Kon, O.L. et al., 1999; Martinenghi, S. et al., 2002; Wang, L.Y. et al., 2003; Yin, D. et al., 2001 ], but few studies have achieved the therapeutic levels of processed insulin that we observed. Nevertheless, the ultimate goal of regulated insulin production will be very difficult to achieve. An alternative approach for the future, however, might be to apply gene therapy to promote islet-cell proliferation or regeneration, and/or to protect islet cells from injury or apoptosis. Some incretin hormones [Edwards, C.M., 2005; Hansotia, T. et al., 2005] , for example, have properties that appear suitable for this purpose.
Leptin Gene Therapy in Models of Obesity and Diabetes
Leptin is predominantly produced by adipocytes and is a key regulator of body weight. Loss-of-function mutations of the leptin gene or its receptor in mice results in syndromes of obesity and type 2 diabetes (ob/ob and db/db mice, respectively). Although human obesity is only rarely caused by these mutations, the administration of leptin might ameliorate obesity from other causes. Therefore, there has been considerable interest in developing leptin gene therapy for the control of obesity. This was can be done with viral vectors, but it was also demonstrated to be possible by transfer of the leptin gene in muscle, using either a hydrodynamic method [Xiang, L. et al., 2003] , or EP methods [Wang, X.D. et al., 2005; Wang, X.D. et al., 2003; Xiang, L. et al., 2003] . In mice treated by electroporation, elevated serum leptin concentrations up to 90 ng/ml were recorded (> 200 fold increase over control mice). Indeed, electrogene transfer resulted in hyperleptinemia, decreased food intake and lower body weight. Furthermore, the production of insulin was lowered in treated mice, but their blood glucose remained normal. Wang et al. [Wang, X.D. et al., 2005] also analyzed the effects of several parameters on the transfection of electroporated muscle. They observed that gene transfer in diabetic mice could be achieved by electric field strengths as low as 75V/cm. They postulate that diabetic muscle is more permissive to EP, although a direct comparison with normal muscle was not included. In rats, a higher voltage (175 to 200V/cm) was required for effective transfection, while rabbits responded poorly under all these conditions.
Gene Therapy to Promote Wound Healing
A major application of EP might be in the treatment of cutaneous wounds that occur in many clinical settings and are particularly difficult to treat in diabetic patients. The cost of treating poorly healing foot wounds in the United States has been estimated at $1 billion per year [Cupp, C.L. et al., 2002] . Recent studies in preclinical models have shown that electrogene transfer can be performed in skin wounds [Byrnes, C.K. et al., 2004] . Wound-localized electrogene transfer of DNA encoding either keratinocyte growth factor [Marti, G. et al., 2004] or TGF-β [Lee, P.Y. et al., 2004] was beneficial in diabetic mice. Notably, in the latter study, TGF-β and EP appeared to act synergistically to promote healing. Since EP has been applied in patients for other purposes, as noted previously, it could probably be applied to promote wound healing, and this will undoubtedly be an area of future clinical investigation.
SYSTEMIC THERAPY IN OTHER APPLICATIONS
Erythropoietin (EPO)
Several studies have documented the feasibility of EPO therapy by plasmid-based electrogene transfer. For instance, Rizzuto et al. [Rizzuto, G. et al., 1999] demonstrated that EP can increase the production and secretion of recombinant protein from mouse skeletal muscle more than 100-fold. Therapeutic EPO levels were achieved in mice with a single injection of as little as 1µg of plasmid DNA, and the increase in hematocrit was long-lasting. Furthermore, they achieved pharmacological regulation of vector expression through a tetracycline-inducible promoter. Tissue damage after EP was transient. Others, with similar methods, have shown EPO production for well over a year in rats and mice [Muramatsu, T. et al., 2001b] . EPO electrogene therapy has been applied to the treatment of mice with beta-thalassemia [Payen, E. et al., 2001] . These authors found that this procedure induced very high hematocrit levels in beta-thalassemic mice compared to non-electrotransferred mice. This was associated with a high transgenic EPO blood level in all mice (up to 2500mU/ml of plasma). EPO electrogene transfer also increased the lifespan of erythrocytes of thalassemic mice. This was related to a nearly complete reestablishment of alpha/beta globin chain balance, and 8 months after the first gene transfer reinjection of the same vector raised the hematocrit to a level close to that observed following the first electrotransfer. EPO electrogene therapy has been successfully applied to animals with renal disease [Ataka, K. et al., 2003; Maruyama, H. et al., 2001] . It is also applicable to non-human primates . Interestingly, gene transfer can be improved considerably by administration of either hyaluronidase [Mennuni, C. et al., 2002] or poly-L-glutamate [Nicol, F. et al., 2002] . Muscle is not the only possible site of EPO plasmid delivery, since positive results have been obtained in rats by a skin-targeted approach [Maruyama, H. et al., 2001] .
To avoid adverse effects such as polycythemia or hypertension, it would be desirable to use regulatable EPO vectors. As noted above, this can be done with tetracyclinesensitive promoters, but it has also been accomplished with the mifepristone-sensitive GeneSwitch system [Terada, Y. et al., 2001; Terada, Y. et al., 2002] .
Generation of DCs by Administration of Plasmids Encoding GM-CSF and FLT3 Ligand (FLT3-L) Hematopoietic Factors
The use of DCs as cellular vectors for immunotherapy is a promising strategy [Palucka, A.K. et al., 2005; Sheng, K.C. et al., 2005] . However, the fact that only small numbers of DCs can be isolated from tissues has been a limitation. The hematopoietic growth factor FLT3-L dramatically increases the numbers of DCs and their progenitors in lymphoid and non-lymphoid tissues [Dong, Y.L. et al., 2003; Pulendran, B. et al., 2001] . In addition, this factor induces the recirculation of CD34 + hematopoeitic cells (HPCs). FLT3-L appears to mediate its effects by targeting primitive progenitors in hematopoietic organs, and by inducing their expansion and differentiation under the influence of additional molecular interactions. However, repeated injections of large amounts of protein are required to induce these effects, and the high cost of producing purified FLT3-L continues to limit this technique. GM-CSF is another cytokine that has key effects on DC maturation and function. In vivo, GM-CSF acts by promoting myelopoiesis, regulating the differentiation and proliferation of myeloid DCs, granulocyte and macrophage progenitors, and peripheralizing these hematopoietic precursors. We demonstrated that we can expand DC numbers in the spleen by intramuscular plasmid-based delivery of either FLT3-L or GM-CSF cDNA. Notably, coinjection of the two genes was markedly superior to either gene alone [Peretz, Y. et al., 2002] .
When we injected FLT3-L or GM-CSF plasmids followed by EP individually into mice the total number of CD11c + /MHC II + DCs increased significantly. FLT3-L therapy yielded a mean of 1.1 x 10 7 CD11c + /MHC II + DCs, but VR-GM-CSF was much more potent yielding 2.3 x 10 7 DCs. When both constructs were injected simultaneously the effect was additive yielding 3.6 x 10 7 CD11c + /MHC II + DCs, which represents a 6-fold increase over blank-vector treatment. This peak was attained 7 days following i.m. injection, and subsequently DC numbers declined to control levels by day 14. We attribute this drop in DC numbers to the concurrent decline in serum cytokine levels following i.m. injection. In accordance with the findings of Parajuli et al. [Parajuli, P. et al., 2001] , our results show that FLT3-L gene transfer expands preferentially the CD11c + CD8α + DCs, contrarily to GM-CSF which expands almost solely CD11c + CD8α -DCs. To address the functional characteristics of the DCs expanded in our experiments, we examined their capacity to stimulate T-cells in MLC. Enriched DCs from the treated or untreated mice were able to stimulate allogeneic Tcell proliferation in a dose-dependent manner. However, we observed a more potent T-cell proliferation when stimulator DCs originated from mice treated with FLT3-L vector alone, compared to any group receiving GM-CSF. Furthermore, flow cytometric analysis of MHC II, B7-1, B7-2 and CD40 expression revealed no upregulation of these surface markers on DCs of mice coinjected with FLT3-L and GM-CSF plasmids. Upregulation of these markers is characteristic of a maturing DC and, consequently, our technique does not appear to markedly change the maturity profile of expanded DCs. In conclusion, we found that intramuscular plasmidbased codelivery of GM-CSF and FLT3-L cDNA is an effective, simple and inexpensive method for generating DCs. Recently, Shimao et al. [Shimao, K. et al., 2005] have reported results similar to ours in the application of FLT3-L gene therapy. This method simplifies the usual in vivo DC expansion protocols, which rely on purified protein injections and could find many applications in immunotherapeutic studies.
Factor VIII or IX Therapy of Hemophilia
Muscle-based eletrogene transfer of factor VIII or IX is a promising approach for the treatment of hemophilia. Long et al. [Long, Y.C. et al., 2004] have shown that skeletal muscle is capable of high factor VIII transgene expression, resulting in 100% phenotypic correction in mice with hemophilia A. These authors found that pretreatment of muscle with hyaluronidase improved transfection efficiency considerably, allowing application of lower electric field strength and, hence, reducing muscle injury.
Similarly, significant plasma levels of factor IX have been reported after in vivo EP of murine skeletal muscle [Bettan, M. et al., 2000] . The intramuscular electrotransfer method produced a 30-to 150-fold increase in protein secretion, compared to simple plasmid DNA injection, generating levels of up to 220ng/ml of human factor IX protein and 2200ng/ml of the SEAP reporter protein. The mice produced antibodies against these xenoproteins, limiting the length of expression. However, in immunodeficient mice SEAP or factor IX were produced for months. Fewell et al. [Fewell, J.G. et al., 2001 ] administered a plasmid encoding human factor IX formulated with "protective, interactive, noncondensing" (PINC) polymers into skeletal muscle followed by the application of EP. They demonstrated long-term expression in mice, as well as the ability to re-administer the plasmid. In normal dogs, they obtained expression of human factor IX at 0.5 to 1.0% of normal levels. However, the response was transient in dogs due to the development of antibodies against human factor IX. They also reported increased circulating creatine kinase levels and histological evidence of transient minor muscle injury associated with the procedure. These results show that EP-based gene therapy with factor IX is feasible in a large animal, but it will be important to administer syngeneic protein, and possibly take other measures that limit immunity against the protein.
Muscle-Based Production of Antibodies
One of the most exciting possibilities involves the use of muscle as a biofactory to produce antibodies. Indeed, administered H and L chain genes expressed on either one or two vectors, with similar success. Using fully murine antibody constructs, they were able to obtain antibody levels in the low therapeutic range that persisted for over 7mon in mice. Without EP at the injection site, only low levels of antibodies were produced. This approach generated levels of up to 750ng/ml in mice, peaking at 3 to 5wk, followed by a slow decline (300ng/ml at 7mon). These antibodies were functional, and could deplete cells bearing a target antigen in vivo. Interestingly, sheep injected with only 100µg of plasmid DNA (an amount that has been used in mice) produced significant levels of antibody (30 to 50ng/ml), but this was interrupted early by the host immune response to the mouse monoclonal antibody. Evidently, it is essential to construct antibodies that are syngeneic to the recipient. Perez et al. [Perez, N. et al., 2004] obtained similar results but, in addition, their vector contained a tetracyclinesensitive promoter (tet-off), allowing negative regulation of expression. The levels of antibody they achieved were in the range of 800 to 1500ng/ml, which is lower than levels reported with viral vectors [Bakker, J.M. et al., 2004; Lewis, A.D. et al., 2002] . However, viral vectors have the severe limitation that the immune system of the recipient can respond to the vector and terminate its action permanently. In constrast, the plasmid vector can be administered repeatedly to sustain adequate levels of antibodies over months, and possibly years, in long-lived species.
A potential caveat is that the antibody levels produced in these studies are relatively low. Many factors affect antibody effectiveness, but plasma concentrations in the range of 3 to 30µg/ml are often required to neutralize a target molecule therapeutically [Bakker, J.M. et al., 2004] . However, our studies in large animals, with EP-enhanced secreted reporter gene transfer, reveal that these serum protein levels can be readily achieved. Thus, it seems likely that therapeutic levels can be produced in humans.
GHRH Gene Transfer Provides the Tools to Test Its Role as an Immunomodulator
In our laboratory, we have studied the local and systemic effects of a single dose of a plasmid expressing growth hormone-releasing hormone (GHRH), in a number of animal species and applications. Hypothalamic GHRH stimulates growth hormone (GH) secretion from the anterior pituitary gland, but recent studies have also demonstrated the immunomodulatory properties of this peptide [Alt, J.A. et al., 2005; Siejka, A. et al., 2004] . Unlike other peptide hormones, GHRH is relatively unattractive as a long-term therapeutic option. The 6min half-life of the hormone and the lack of oral bio-available formulations call for frequent (2 to 3 times daily) i.v or s.c. administrations [Campbell, R.M. et al., 1994] . On the other hand, the hypothalamic hormone is a more physiological method to stimulating both the immune system and GH axis, maintaining the pulsatile release of GH, stimulating all GH isoforms (known for their divergent effects on target tissues and organs) in a natural proportion [Nuoffer, J.M. et al., 2000; Takahashi, S. et al., 2002] , and responding to endogenous feed-back regulation. A number of constructs encoding for species-specific or analog GHRH have been tested to treat anemia and cachexia associated with cancer and its treatment [Draghia-Akli, R. et al., 2002a; Tone, C.M. et al., 2004] , and renal failure, as well as to increase immune surveillance and animal welfare [Brown, P.A. et al., 2004; Thacker, E.L. et al., 2006] .
Dogs With Spontaneous Malignancies
Studies in dogs showed that a single administration of a GHRH plasmid into skeletal muscle ensured physiologic GHRH expression for months . A study in cancer-afflicted dogs [Draghia-Akli, R. et al., 2002a ] demonstrated a significant increase in circulating lymphocyte levels. Furthermore, a study of severely debilitated geriatric dogs, or dogs with spontaneously occurring tumors, showed IGF-I levels restored to normal for more than one year post-treatment. We have observed increases in weight, activity level, exercise tolerance, and improvement and maintenance of hematological parameters. The longterm assessment of the treated dogs showed improvement in quality of life that was maintained throughout the study [Tone, C.M. et al., 2004] . These results suggest a role for plasmid-mediated GHRH treatment in reversing the catabolic processes associated with aging and cancer anemia and cachexia, and that the improved well-being may be associated with stimulation of immune function.
Dairy Cattle
In this study, 52 Holstein cows were evaluated for the effects of a plasmid-mediated GHRH treatment on their immune function, morbidity and mortality [Brown, P.A. et al., 2004] . In the third part of pregnancy, 32 heifers received 2.5mg of a GHRH-expressing plasmid by i.m. injection followed by EP. Twenty heifers were used as controls. No adverse effects were associated with the plasmid delivery or GHRH expression. At day 18 after plasmid administration, GHRH-treated animals had increased numbers of CD2 + αβ T-cells (P<0.004), increased CD25 + CD4 + cells (P<0.0007), and CD4 + CD45R + cells (P<0.016) compared to controls. These increases were maintained long-term and correlated with plasmid expression. At 300d post-GHRH treatment, CD45R + /CD45R0-naïve lymphocytes were significantly increased in frequency (P<0.05), as were natural killer lymphocytes (CD3 -CD2 + ). As a consequence of improved health status, body condition scores improved (3.55 in treated animals vs 3.35 in controls, P<0.0001). The mortality of heifers was decreased (3% in treated vs 20% in controls, P<0.003). Collectively, these results indicate that the GHRH plasmid can be successfully electro-transferred into a 500kg mammal and expressed long-term, ensuring physiological levels of GHRH.
Pigs Vaccinated and Challenged with Mycoplasma hyopneumoniae (M. hyo.)
The purpose of this pilot study was to evaluate the efficacy of a single dose of 0.625mg of a porcine GHRHexpressing plasmid to decrease symptoms of mycoplasmal pneumonia and improve the clinical outcome after vaccination and challenge [Thacker, E.L. et al., 2006] . Pigs were vaccinated with RespiSure® on trial days 7 and 21. Pigs were challenged intratracheally at 2wk after the second vaccination with a tissue homogenate containing a derivative strain of pathogenic M. hyo. [Thacker, E.L. et al., 1998 ]. When all weight data were evaluated between M. hyo challenge and the first necropsy we observed that the plasmidtreated group had a significantly greater average daily gain (ADG) than the control group. This was a significant finding, as treated subjects maintained normal growth even when faced with a pathogenic challenge, confirming that physiologic GHRH levels can favor anabolic processes even in acute and chronic phases of critical illness [Van den, B.G., 2003] . These results also confirm other studies demonstrating a strong negative correlation between ADG and the lung lesion score [Dawson, A. et al., 2002] . M. hyo serum antibodies (0.43±0.06 in treated-animals vs 0.29±0.05 in controls) and M. hyo bronchioalveolar lavage (BAL) fluid antibodies (0.88±0.04 in plasmid GHRH-treated vs 0.69±0.05 in controls, P<0.03) were increased in GHRH-treated group. Such local humoral immunity, as in BAL, appears to play an important role in the infection with M. hyo [Sarradell, J. et al., 2003] . Respiratory scores and coughing scores were significantly improved (P<0.05). The positive change in circulating and local antibodies may have allowed the GHRHtreated group to respond more rapidly to the challenge and thus explains the increased airway responsiveness and decreased clinical pathology in this group.
Effects of Plasmid-Mediated GHRH Therapy on Body Composition, Weight Gain, Morbidity and Mortality
In many studies, we have tested a GHRH-expressing plasmid expressed in skeletal muscle following intramuscular injection enhanced by electroporation. The GHRH is released in the systemic circulation, and ectopically stimulates the animal's pituitary to produce and release growth hormone (GH) and insulin-like growth factor-I (IGF-I). Young pigs directly injected with as little as 0.1 mg of a GHRHexpressing plasmid had significantly greater weight gain than controls, and significant increase in lean body mass, and a decrease in fat mass . We also have demonstrated that the offspring of gilts (250-400 kg) injected intramuscularly and electroporated at day 85 of gestation with 1-5 mg of a GHRH-expressing plasmid have optimized growth characteristics due to both improved intrauterine weight gain, and enhanced maternal lactation performance. Thus, the piglets from treated gilts were larger at birth and weaning compared to controls and exhibited a significantly reduced morbidity and mortality . An important finding is that the analysis of more than 300 treated animals revealed that expression was maintained for at least 1 year, and the beneficial effects on the offspring occurred for three consecutive pregnancies in the treated animals after one single plasmid administration (expression driven by a synthetic muscle specific promoter [Li, X. et al., 1999] , plasmid delivered by i.m injection + constant current EP) without redosing (Draghia-Akli, manuscript in preparation).
The positive results obtained with plasmid-based GHRH in companion and farm animals prove that by combining adequate plasmid design with the EP method, one can obtain physiologic levels of a transgene product even in a 500kg animal, giving hope that soon this and other applications may be translated to a number of human applications.
NONVIRAL GENE TRANSFER IN HUMANS
There have been questions as to whether nonviral gene therapy and/or DNA vaccination are effective in large mammals. Therapeutic levels of angiogenic factors have been generated in human skeletal and cardiac muscle even without EP [Isner, J.M., 2002] . Moreover, as discussed previously, EP-enhanced plasmid-based gene transfer for DNA vaccination or other purposes has been successfully performed in pigs, dogs, ruminants, horses, non-human primates and humans. Electrogene transfer is likely to be useful for cancer therapy, because EP has been useful to enhance Bleomycin chemotherapy and the technique is readily adaptable to gene transfer.
Early studies examined the use of electrochemotherapy using bleomycin in metastatic melanoma [Glass, L.F. et al., 1996b] and basal cell carcinoma [Glass, L.F. et al., 1996a] . More recent studies have examined the effects of bleomycin in metastatic melanoma [Byrne, C.M. et al., 2005] , with 13 of 18 patients showing a complete response. A larger Phase II study using bleomycin in patients with advanced squamous cell carcinoma of the head and neck demonstrated a 57% partial or complete response to the treatment [Bloom, D.C. et al., 2005] . Currently, there are five clinical trials on going involving the electroporation of tumors. Of these studies, four involve delivery of bloemycin to head and neck or cutaneous/subcutaneous cancer. The fifth study is evaluating the safety of intratumorally injected plasmid VCL-IM01 (expressing HLA-B7 and β-2 microglobulin) into patients with metastatic melanoma (for detailed information regarding the clinical trials, see www.clinicaltrials.gov).
Most of the human studies have been in the area of DNA vaccination, although EP was not applied. Notably, as reviewed previously, immune responses can be generated against malaria antigens by i.m. DNA vaccination and recent studies point to heterologous plasmid/virus prime-boost strategies as an effective method of generating immunity. Antigen-reactive T cells are readily induced, but antibody responses are usually of low magnitude. Preclinical studies suggest that this limitation might be addressed by electrokinetic enhancement. Nonviral DNA transfer into humans has had a remarkable safety profile and thus is attracting more attention.
CONCLUSIONS AND FUTURE PROSPECTS
Nonviral gene therapy holds great promise for the treatment of many diseases. Unlike protein therapy, it allows long-term and relatively constant delivery of many protein drugs. In our laboratories, we have relied primarily on administration of expression plasmids into skeletal muscle. These vectors are nonimmunogenic and can be expressed in muscle for months. However, nonviral vector expression has been much superior in rodents than in large animals. This problem of scalability has been addressed in various ways, but the application of EP remains one of the simplest and most effective methods of gene transfer. Electrogene transfer is versatile and safe, and can be used to deliver nucleic acid fragments, oligonucleotides, siRNA, and plasmids to a wide variety of tissues in addition to muscle.
In this review, we establish that gene transfer using electroporation can be effectively applied in both small and large animals (rodents, dogs, pigs, other farm animals, and primates). We also outline how electric fields can be optimally applied to maximize gene expression, while minimizing tissue injury. This approach has been successfully employed in preclinical autoimmune and/or inflammatory diseases to deliver either cytokines, anti-inflammatory agents, or mutated costimulatory molecules. Numerous studies have demonstrated effectiveness in the intratumoral delivery of therapeutic vectors. Importantly, it has been found to be highly effective in boosting DNA vaccination against a wide variety of antigens, of relevance to infection, cancer or autoimmunity. One of the most promising applications, however, is in the systemic delivery of protein drugs, such as endocrine hormones, hematopoietic factors, antibodies, enzymes, and others. This is supported by the numerous pre-clinical studies demonstrating systemic delivery of these agents. The muscle is ideally suited for this "biofactory" function because of its size, easy accessibility, high vascularity, and stable (non-dividing) cell population. Futhermore, musclebased gene expression can be remarkably long, which provides an enormous economic advantage over classical protein therapy. It is evident that nonviral systemic gene therapy will be most readily applicable to agents that do not have to be tightly regulated in their level of expression over time (e.g., factor VIII, cytokine receptors, antibodies, some hematopoietic factors), but regulatable vectors with various genetic switches can also be employed when necessary. The feasibility of these approaches in large animals, including pigs and non-human primates, is a clear indication that they could be also be applied to human disease. This is further supported by the current clinical application of EP to enhance some forms of cancer therapy.
The use of nonviral nucleic acids in experimental therapy is constantly expanding. The most remarkable new development, however, is the introduction of siRNA-based therapeutic agents. Indeed, synthetic or vector-delivered siRNAs are powerful new tools for gene silencing, and their potential therapeutic applications are numerous. However, targeting the in vivo delivery of these molecules to a specific tissue is difficult, and electroporation-enhanced nonviral methods of nucleic acid transfer have advantages in terms of simplicity, effectiveness and safety.
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